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 It is increasingly recognized that a patient’s response to a medical treatment is a statistically 
heterogeneous phenomenon. The average treatment effects may not represent a heterogeneous 
population of patients. The benefits each patient receive from the treatment could differ, requiring 
measurement of treatment benefits at the patient level. Despite of the development of methods in 
this field, new methods are needed for predicting individual treatment benefits using longitudinal 
binary outcomes or hospital data with nonignorable missingness.  
 This dissertation has three main chapters. Chapter 1 introduces a method for predicting 
individual treatment benefits based on a personalized medicine model that implements random 
effects logistic regression of binary outcomes that may change over time. The method uses 
empirical Bayes (EB) estimators based on patients’ characteristics and responses to treatment. The 
prediction performance is evaluated in simulated new patients using correlations between the 
predicted and the true benefits as well as relative biases of the predicted benefits versus the true 
benefits. As an application, the method is used to examine changes in the disorganized dimension 
of antipsychotic-naïve patients from an antipsychotic randomized clinical trial.  
 Chapter two of the dissertation presents a method for predicting individual treatment 
benefits with a novel 2-dimensional personalized medicine model that handles non-ignorable 
missingness due to hospital discharge and evaluate its reliability and accuracy by simulations. The 
longitudinal outcome of interest is modeled simultaneously with the hospital length of stay through 
a joint mixed model. The method is illustrated with an application assessing individual pain 
management benefits post spine fusion surgery. EB-Predicted individual benefits are compared 
with Monte-Carlo computed benefits. Pearson’s correlations and relative biases are used to assess 
the prediction accuracy.  
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 Finally, Chapter three of the dissertation applies the methodology developed in Chapter 
two to analyze with more clinical detail the impact of depression and age on individual benefits of 
postoperative pain management in lumbar spinal fusion patients using Cerner HealthFacts® 
electronic health records. The developed joint multivariate mixed model of pain scores and length 
of hospital stay is used to analyze individual benefits. The effects of depression and age on the 
amount and rate of change of the pain management benefits are evaluated, as well as the 
association between individual benefits and post-surgical hospital length of stay.  
We conclude that the utilization of the EB prediction of individual treatment benefits is 
useful in the analyses of treatment effects using not only clinical trial data but also electronic health 
records. Predicted individual treatment benefits are accurate when model parameters are reliably 
estimated. 
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Chapter 1: Measuring individual benefits of psychiatric treatment using longitudinal binary 
outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users   
In collaboration with Drs. Benedicto Crespo-Facorro, M.D., Jose de Leon, M.D., and Francisco J. Diaz, 
Ph.D. 
(See collaborator affiliations in Acknowledgements) 
1.0. Abstract 
 We present and evaluate a method for predicting individual treatment benefits based on random 
effects logistic regression models of binary outcomes that change over time. The method uses empirical 
Bayes estimators based on patients’ characteristics and responses to treatment. It is applicable to both 1-
dimentional and 2-dimentional personalized medicine models. Comparisons between predicted and true 
benefits of simulated new patients using correlations and relative biases were used to evaluate prediction 
performance. The predicted benefits had relatively small relative biases and relatively high correlations 
with the true benefits in the simulated new patients. The predictors also captured overall population trends 
in the evolution of individual benefits. The proposed approach can be used to retrospectively evaluate 
patients’ responses in a clinical trial, or to retrospectively or prospectively predict individual benefits of 
different treatments for new patients using patients’ characteristics and previous responses. The method is 
used to examine changes in the disorganized dimension of antipsychotic-naïve patients from an 
antipsychotic randomized clinical trial. Retrospective prediction of individual benefits revealed that more 
cannabis users had slower and lower responses to antipsychotic treatment as compared to non-cannabis 
users, revealing cannabis use as a negative prognostic factor for psychotic disorders in the disorganized 
dimension. 





Randomized clinical trials (RCT) are often used to establish the best treatment for the average 
patient. Heterogeneity in patients’ responses are largely overlooked. In the era of personalized medicine, 
which perceives patients’ responses to medications as a heterogeneous phenomenon (de Leon, 2012; 
Ruberg et al., 2010; Sies et al., 2019; Xu and Hedeker, 2001), it is essential to develop statistical tools for 
the analysis of individualized treatment benefits in RCTs that guide therapy in medical practice.  
The statistical approaches developed in recent years for establishing personalized treatment rules 
or predicting individualized treatment benefits include methods based on generalized linear mixed-effects 
models (Andrews and Cho, 2018; Botts et al., 2008; Cho 2017; Diaz, 2016, 2017; Diaz et al., 2007, 2008, 
2012a, 2012b, 2013a, 2013b, 2014; Senn, 2016;  Zhu and Qu, 2016), penalized regression for high-
dimensional data (Boulesteix et al., 2017; Kim et al., 2017; Ma et al., 2016), and machine learning methods 
(Goldstein et al., 2017; Powers et al., 2018). Among them, generalized linear mixed-effects modeling is an 
excellent tool for predicting individuated treatment benefits. Diaz (2016, 2019) proposed the concepts of 
1-dimensional personalized medicine (1-PM) and 2-dimensional personalized medicine (2-PM) models for 
treatments of chronic diseases using mixed effects. These models use random effects in addition to fixed 
effects to represent the heterogeneity of patients’ characteristics including unknown traits. If the random 
effects only include a random intercept representing unexplained patient variability before treatment 
administration, then the model is considered a 1-PM model. In this case, the treatment effect is fixed in the 
sense that it is independent of the patient. If the random effects additionally include random coefficients 
whose variabilities are explained by differences in the treatment effect across patients, then it is considered 
a 2-PM model (Diaz 2016, 2019). While treatment effects are still measured with regression coefficients 
other than the intercept, the individual treatment benefit is a dimension that may also depend on some of 
the patient’s known or unknown baseline characteristics.   
Cannabis is a psychoactive drug widely used around the world; it has a significant impact on mental 
and physical health (Barrigón et al., 2010; Cobo et al., 2017; Legleye, 2018). Cannabis use has been shown 
to be associated with increased risk of developing psychotic disorders as well as adverse outcomes in 
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patients with psychosis (Linszen et al., 1994; Moore et al., 2007; Zammit et al., 2008). Multiple cohort 
studies suggest that cannabis abuse leads to more severe psychotic symptoms in patients with psychosis or 
schizophrenia (Caspari, 1999; Grech et al., 2005; Foti et al., 2010; Kuepper et al., 2011). Cannabis use is 
also known to be associated with increased relapse and non-adherence (Hides et al., 2006; Linszen et al., 
1997; Schoeler, 2016). Clausen et al. (2014) found that patients who stopped using cannabis had a 
significantly lower level of psychotic symptoms after adjusting for baseline conditions and medications.  In 
our pragmatic RCT of patients with a first episode of non-affective psychosis, after adjusting for potential 
confounders, cannabis use was associated with poorer responses to antipsychotic treatment when responses 
were measured with the disorganized or the positive dimensions of the Scale for the Assessment of Positive 
Symptoms and Negative Symptoms (SAPS-SANS) (Andreasen, 1983a, 1983b; Pelayo-Teran et al., 2014).  
The objective of the current study is three-fold. The first is to extend the methodology for measuring 
individual treatment benefits proposed by Diaz (2016, 2019) to longitudinal binary outcomes, which utilizes 
empirical Bayesian (EB) predictors of individual benefits. This is necessary because patients’ responses to 
treatment may change over time, whereas the previous approach to measuring individual benefits with 
binary outcomes considered only stable post-treatment responses (Diaz, 2016). The second is to evaluate 
the performance of the proposed EB predictors by showing that they correlate with the true benefits 
achieved by simulated hypothetical new patients and showing that the predictors can also reflect overall 
clinical population trends. The third is to illustrate the methodology by measuring the individual benefits 
of antipsychotic treatment and showing how cannabis use affects these, using the disorganized dimension 
scores of the SAPS-SANS scale from the patients of our pragmatic RCT (Pelayo-Teran et al., 2014).  
In Section 2, we present the methods used for this study. Section 2.1 describes 1-PM and 2-PM 
logistic regression models for longitudinal responses that evolve over time.  Section 2.2 describes disease 
severity measures and benefit functions under the logistic model. Section 2.3 describes how individual 
benefits can be calculated for each time point using EB prediction. Section 2.4 introduces the application 
of the proposed method of benefit prediction in the analysis of data from the antipsychotic RCT (Pelayo-
Teran et al., 2014). Section 2.5 describes two methods for evaluating the performance of EB predictors. 
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One compares their distribution with estimates obtained through Monte Carlo computations, and the other 
implements simulations of hypothetical new patients. The model and analysis for the antipsychotic RCT 
are in Sections 3.1 and 3.2.  Results of the evaluations of EB predictors are in Sections 3.3, 3.4 and 3.5. A 
discussion is in Section 4. 
1.2. Methods  
1.2.1 Time-dependent personalized medicine models for binary outcomes 
We assume that the treatment response is a binary outcome of ‘1’ (‘Yes’) versus ‘0’ (‘No’), with 1 
indicating a good condition for the patient. This also applies to controlling the measurement of a continuous 
or ordinal response such that it is below or above a pre-set value or within a pre-set range, for instance, 
dichotomizing a response for which the assumptions of alternative regression models may not be valid. For 
example, as a therapeutic target, we may want to reduce the discrete disorganized dimension score (ranged 
0-15) of a psychiatric patient to less than or equal to 3. The response is defined as 1 if the measurement is 
≤ 3, and 0 if it is > 4. We also assume that the responses vary over time, which is often the case in medical 
treatments.  
We used mixed-effects logistic regression models to predict the treatment benefits. The binary 
outcome is denoted as 𝑦𝜔,𝑗 where 𝜔 represents a subject (or patient) and 𝑗 a specific observation at a given 
time point 𝑡𝜔,𝑗. The 2-PM logistic model is  
               
 logit (𝑃(𝑦𝜔,𝑗 = 1|𝑿𝜔, 𝑡𝜔,𝑗)) = 𝛼0,𝜔 + 𝝀
𝑇𝑿𝜔  + ∑ 𝛽𝑘
𝑛
𝑘=0
𝑔𝑘(𝑡𝜔,𝑗) +   ∑ 𝛼𝑘,𝜔
𝑛
𝑘=1
𝑔𝑘(𝑡𝜔,𝑗), (1)  
 𝜔 = 1, … , 𝐼, 𝑗 = 1, … , 𝐽𝜔    
where 𝐼 indicates number of subjects used to estimate model parameters, 𝐽 indicates number of observations 
for subject 𝜔,  𝑿𝜔 indicates patient-level covariates (i.e., a subject’s characteristics) with fixed effects, 𝑔𝑘 
are functions of time, 𝛽𝑘 and 𝝀 are fixed effects (population constants). 𝛼𝑘,𝜔 (𝑘 ≥ 0) are random effects in 
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the sense that each patient has their own values. Usually, 𝛼𝑘,𝜔 are considered normally distributed with 
mean 0 (Hedeker & Gibbons, 2006; White et al., 2003). When 𝛼𝑘,𝜔 = 0 for 𝑘 ≥ 1, Formula (1) reduces to 
a 1-PM model. 
 A usual choice for 𝑔𝑘(𝑡) is 𝑡
𝑘, 𝑘 = 0, … , 𝑛, which models the evolution of the response over time with a 
polynomial trend of degree 𝑛. Here, however, 𝑔0(𝑡), … , 𝑔𝑛(𝑡) represent orthogonal polynomials of degree 
0, … , 𝑛, respectively, which facilitate numerical computations and are interpreted similarly (see Section 
2.4) (Emerson, 1968; Pettofrezzo, 1984; Hamming, 1987; Hedeker and Gibbons, 2006).                                                      
1.2.2 Disease severity and individual benefits  
Once model parameters are estimated, we can use them to “predict” (estimate) individual treatment 
benefits, not only for patients from the clinical trial but also for new patients. The severity of a patient’s 
chronic disease at a given time point is defined as the probability that the patient’s response is outside the 
therapeutic target (Diaz, 2016). At time 0, that is, before treatment starts, the severity is  
𝑠0 = 1 − (1 + exp (−𝛼0 − 𝝀






where the index 𝜔 is not written in the equation to emphasize that the patient may be a new patient and 𝛼0 
is a patient-specific intercept. 
The severity for the patient at time 𝑡 post treatment initiation is  
𝑠𝑡 = 1 − (1 + exp (−𝛼0 − 𝝀
𝑇𝑿 −  ∑ 𝛽𝑘
𝑛
𝑘=0






The individual benefit of the treatment is the reduction in disease severity from time 0 (Diaz, 2016, 2019). 
Thus, the patient’s benefit after 𝑡 units of time under treatment is 
𝑏(𝑡; 𝝀, 𝜷, 𝜶, 𝑿)  = 𝑠0 − 𝑠𝑡            (2) 
where  𝜷 = (𝛽0, … , 𝛽𝑛)
𝑇, and 𝜶 = (𝛼0, … , 𝛼𝑛)
𝑇 is the vector of patient-specific random effects.     
1.2.3 Empirical Bayesian prediction of individual benefits 
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For calculating the predicted individual treatment benefits at a given time point, we need to estimate 
the random effects for each patient. For the current study, the command for multilevel mixed-effects 
generalized linear models (“meglm”) in the Stata software was used to fit the mixed-effects logistic model 
and obtain EB means as predictors of the random effects 𝜶 (version 15.1, StataCorp LLC, College Station, 
TX). Once parameter estimates are obtained for the mixed-effects model, Stata’s “predict” command only 
needs the responses and covariates of a patient, either from the original sample or as a new patient, to predict 
the patient’s random effects. The command combines the specific patient’s data with the estimated model 
parameters to compute the predictions. The EB predictor of the patient’s random effects is an estimate of 
the mean of the conditional (posterior) distribution of the random effects given the patient’s data. Stata’s 
predict command computes this estimate using adaptive Gaussian quadrature (Skrondal and Rabe-Heketh, 
2004).  
If ?̂?  is the EB predictor of a patient’s  𝜶, the EB predictor of the individual benefit at time 𝑡 ≥ 0 
is   
𝑏(𝑡; ?̂?, ?̂?, ?̂?, 𝑿)             (3) 
where ?̂? and ?̂? are the maximum likelihood estimates of 𝝀 and 𝜷.  
Here we adopt standard EB terminology and use the term “predictor” to refer to an estimator of a random 
coefficient or an individual benefit, which are random variables at the patient population level (Robinson, 
1991). In this sense, the term prediction does not refer to the forecast of future values of 𝑦. We restrict the 
term “estimator” to estimators of fixed effects or variance components.   
1.2.4 Application to an antipsychotic RCT: retrospective empirical Bayesian prediction of benefits 
The antipsychotic-naïve patients with non-affective psychosis provided a written informed consent 
to be included in the RCT (Pelayo-Teran et al., 2014), which conformed to international standards for 
research ethics and was approved by the local institutional review board. Here, we analyzed the 
disorganized dimension scores of the SAPS-SANS scale, with higher scores representing poorer outcomes 
(Andreasen, 1983a; 1983b). The dichotomous response 𝑦 was coded as 1 if the subject had a disorganized 
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dimension score  ≤ 3, or 0 otherwise. The responses were available at baseline and at the end of 1, 2, 3, 4, 
and 6 weeks of antipsychotic treatment. One hundred sixty-one patients were randomized to olanzapine, 
risperidone or haloperidol (Pelayo-Teran et al., 2014). Since our goal was to measure individual benefits, 
only the 117 patients with 𝑦 =  0 at baseline were included in these analyses (55 non-cannabis users and 
62 cannabis users). Those within the therapeutic target at baseline (𝑦 =  1) were excluded (26 non-cannabis 
users and 18 cannabis users).  
The final model included cannabis use as a time-independent patient characteristic (Table 1). 
Therefore, in this application, 𝑿 included only cannabis use. As in prior analyses (Pelayo-Teran et al., 
2014), variable selection for the mixed-effects logistic model did not produce any significant differences 
among the three antipsychotics. Similarly, diagnosis, duration of untreated psychosis, gender, and smoking 
did not have significant effects on the odds of being within the therapeutic target. The analyses ruled out 
the possibility that these variables were confounders of cannabis use and the response. 
 
Table 1.  Random intercept logistic regression model of disorganized dimension score less than or equal to 





p-value 95% CI 
Fixed effects    
Cannabis usea -1.647 (0 .7128) 0.021 [-3.044, -0.250] 
Orthogonalized timeb,c 3.722 (0.4242) <0.0001 [2.890, 4.553] 
Orthogonalized time-squareb,d -1.911 (0.3079) <0.0001 [-2.514, -1.307] 
Orthogonalized time-cubeb,e 0.876 (0.2133) <0.0001 [0.458, 1.294] 
Interceptf 0.918 (0.5268) 0.081 [-0.115, 1.950] 
Variance of random effects    
Intercept 10.681 (3.0136)  [6.144, 18.569] 
CI: 95% confidence interval; SE: standard error. 
aThe dichotomous covariate “cannabis use” was defined as 1 if the subject was a cannabis user, 0 otherwise.  
bTime in weeks was transformed into three mutually orthogonal covariates to build a polynomial of degree 3. The 
polynomial represented the evolution over time of the logit of the probability of having a disorganized dimension less 
than or equal to 3.  
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cThe 1st order orthogonal polynomial was 𝑔1(𝑡)  =  1.352 + 0.507𝑡, where 𝑡  is time. The covariate “orthogonalized 
time” was computed with this formula.   
dThe 2nd order orthogonal polynomial was 𝑔2(𝑡) =  1.336 − 1.604𝑡 + 0.267𝑡
2. The covariate “orthogonalized time-
square” was computed with this formula. 
eThe 3rd order orthogonal polynomial was 𝑔3(𝑡) =  1.028 + 3.693𝑡 − 1.713𝑡
2 + 0.190𝑡3 . The covariate 
“orthogonalized time-cube” was computed with this formula.  
fThe zero-order orthogonal polynomial, 𝑔0(𝑡) is the fixed intercept. 
 
Orthogonal polynomials (Emerson, 1968; Pettofrezzo 1984; Hamming, 1987; Hedeker and 
Gibbons, 2006) up to degree 3 were used to model the changes of responses over time (Table 1). The 
orthogonal polynomial representation greatly reduces collinearity and scale differences between time 
powers and simplifies the computation. The transformation of time into orthogonal polynomials is 
especially useful in mixed-effects models since it speeds up the convergence, which can be challenging for 
mixed models. No significant random effects for orthogonally-transformed time powers were observed in 
the random effects logistic model; therefore, only fixed effects were used for the transformed time variables 
and 𝜶 included only a random intercept. The Stata command “orthpoly” was used to transform the time 
variable to orthogonal polynomials (StataCorp LLC, College Station, TX). The “poly” option provided the 
coefficients of the orthogonal polynomials, allowing treatment benefit prediction at specific time points.  
The orthogonal polynomials are reported in footnotes c-e in Table 1. 
Similar to Diaz (2019), we used parameter estimates and data from a specific patient to predict the 
patient’s benefit at time 𝑡 + ℎ. Here, 𝑡 is the prediction origin, defined as the time up to which the patient’s 
data are collected to make the prediction; and ℎ is the prediction horizon, defined as the elapsed time 
between the prediction origin and the time for which we want to predict the benefit. For instance, if we 
have collected data during 3 weeks of treatment and want to predict the patient’s benefit at week 5, then 
𝑡 = 3 and ℎ = 2. If we want to predict the benefit at week 2, then 𝑡 = 3, ℎ = −1.   If ℎ ≤  0, we are 
retrospectively estimating the benefit achieved at time 𝑡 +  ℎ. If ℎ >  0, we are forecasting a future benefit 
value at time 𝑡 +  ℎ (Diaz, 2019). Prediction origin 𝑡 =  0 indicates only baseline responses are available 
for predicting benefits. Although 𝑡 and ℎ can be non-integers, we used only integer numbers.  
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To illustrate how the proposed method can be used in data analysis for retrospective benefit 
predictions, we predicted the benefits for each of the 55 non-cannabis users and 62 cannabis users at weeks 
1 through 6 using Formula (3) and the estimates in Table 1. This formula allows predicting benefits at any 
given time point, even if the clinical trial did not collect data at that point. To compare the evolutions of 
individual benefits over time, the sample quartiles of the 62 EB benefit predictions from cannabis users 
were computed, and similarly for the 55 non-cannabis users (Table 2). These sample quartiles can be 
viewed as estimates of the quartiles of the distributions of individual benefits for the populations of cannabis 
and non-cannabis users 
1.2.5 Assessment of empirical Bayesian predictions 
We conducted Monte Carlo computations as an alternative to the EB approach to estimate 
population quartiles of individual benefits. For cannabis or non-cannabis users at a time point, Monte Carlo 
estimates of population quartiles were obtained by simulating 1,000 patients assuming the model in Table 
1, and then calculating the quartiles of their benefits, as described in Supporting Information S1. The 
estimated population quartiles, reported in Table 3, were compared with the sample quartiles of the benefits 
for the 55 non-cannabis users and 62 cannabis users predicted with the EB approach and reported in Table 
2. We consider an agreement between these two types of estimates as evidence that EB individual benefit 
predictors reflect overall population trends reliably.  
In addition, a simulation study was conducted to evaluate how well EB benefit prediction would 
work in new patients. The simulations assessed the performance of Formula (3) for various prediction 
origins (𝑡), prediction horizons (ℎ), and distances of parameter estimates from true parameters (𝛿) in 
standard error units (Diaz, 2017). Spearman’s correlations (𝐶𝑡+ℎ) between predicted benefits and 
simulated true benefits were computed (Table 4). Relative biases (ℬ𝑡+ℎ), defined as {(mean of bias) / 
(mean of true benefit)} x 100 were used to examine prediction accuracy, where bias is the difference 
between predicted and true benefit (Table 5). The simulation methodology is in Supporting Information 


















































































































































































































































































































































































































































































































1.3. Results  
1.3.1 The impact of cannabis on individual responses to antipsychotic treatment  
A mixed-effects logistic model was used to examine the impact of cannabis use on individual 
treatment effects of antipsychotics. As described above, the response was defined as 1 if the disorganized 
dimension score was ≤ 3, or 0 otherwise. The selected 1-PM model had cannabis as well as orthogonalized 
time, time-square and time-cube as covariates with fixed effects, and a random intercept (Table 1). The 
likelihood of not being in the therapeutic target followed a cubic-polynomial trend over time. On average, 
cannabis use was significantly associated with decreased odds of having a disorganized dimension ≤ 3, 
with an odds ratio of 0.193 (95% CI: 0.048 to 0.779) as compared to no use.  
1.3.2 Retrospectively predicted antipsychotic benefits  
The antipsychotic benefits the subjects received during the RCT were analyzed retrospectively for 
treatment durations of 1 to 6 weeks. Please note that although the RCT measured patients’ responses only 
at the end of weeks 1, 2, 3, 4, and 6, benefits can be predicted for any treatment duration between 0 and 6 
weeks using Formula (3). The medians and the first and third quartiles of the predicted benefits for non-
cannabis and cannabis users are shown in Table 2.  
The quartiles of the benefits for cannabis users were much smaller at earlier weeks as compared to 
non-cannabis users, indicating generally slower responses to the treatment in cannabis users (Table 2). For 
instance, in non-cannabis users, the median decrease in disease severity was 0.235 probability units 
compared to 0.037 for cannabis users at week 1. Treatment benefits tended to increase with time for both 
groups. By weeks 5 or 6, the medians of the benefits are comparable for cannabis users and non-cannabis 
users; however, the first quartile for cannabis users remained much smaller than that for non-cannabis users, 
indicating that there were more cannabis users receiving little benefits than non-cannabis users.  
1.3.3 Comparison of quartile estimates based on empirical Bayesian predictors with Monte Carlo 
estimates 
The patterns of the evolution of EB predicted benefits (Table 2) were like those of the benefit 
evolution suggested by the Monte Carlo approach (Table 3), indicating a reliable estimation of quartiles of 
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treatment benefits when using EB predictors of random effects. Both tables reveal a negative impact of 
cannabis on antipsychotic treatment benefits by delaying the responses in some patients, suggesting a 
moderating effect for cannabis. Although the number of non-cannabis and cannabis users achieving tangible 
benefits increased with time, cannabis users achieved benefits more slowly. Even at the end of week 6, 
there were more cannabis users than non-cannabis users who had not received high benefits yet.   
The variations of the EB predicted benefits over time and the differences between cannabis and 
non-cannabis users are also illustrated using histograms in Figure 1, and analogously for the benefits of the 
1,000 simulated patients per cannabis status group from Monte Carlo computations shown in Figure 2.  
The two figures exhibit similar patterns, suggesting the adequacy of EB predictors for detecting overall 
group trends. For each time point, there were more cannabis users who were not receiving substantial 
benefits compared to non-cannabis users. Even at week 6, there were more cannabis users whose treatment 
benefits remained minimal.  
To visualize how the medians of the retrospectively- predicted EB benefits changed over time for 
non-cannabis versus cannabis users and compare their patterns with the Monte-Carlo computed medians, 
we plotted the medians from Tables 2 and 3 in Panels A and B of Figure 3, respectively.  The medians of 
benefits for cannabis users increased at a slower pace compared to non-cannabis users. The patterns for 
medians of EB predictions (Panel A) are consistent with those for Monte Carlo medians (Panel B), 
suggesting that the medians of EB retrospective predictions accurately captured group trends in benefit 
evolution.   
1.3.4 Evaluation of EB benefit prediction in simulated new patients using correlations between 
predictions and true benefits  
To examine the performance of the benefit predictor in Formula (3), we analyzed the correlations 
between the predicted individual benefits and the true individual benefits from simulated new patients using 
Spearman’s correlations (𝐶𝑡+ℎ). Each 𝐶𝑡+ℎ was calculated from 1,000 simulated cannabis users or 1,000 











































































































































































































































































































































































































































Table 4. Spearman correlations (𝐶𝑡+ℎ) between EB predicted benefits and true benefits of antipsychotic 
treatment in simulated new patients who are cannabis users, by prediction origin (𝑡), prediction horizon 
(ℎ) and distance of parameter estimates from true parameters in standard error units (𝛿).  
  𝑡 + ℎ (weeks) 
𝑡 (weeks) 𝛿 2 4 6 
0 0 -0.07  -0.03  0.01 
 0.5 -0.07 (-0.17, 0.05) -0.03 (-0.17, 0.08) -0.01 (-0.14, 0.15) 
 1 -0.07 (-0.31, 0.08) -0.05 (-0.32, 0.17) 0.01 (-0.28, 0.26) 
 1.5 -0.06 (-0.49, 0.16) -0.06 (-0.49, 0.32) -0.04 (-0.46, 0.33) 
2 0 0.80  0.60  0.61 
 0.5 0.79 (0.75, 0.82) 0.59 (0.47, 0.68) 0.62 (0.50, 0.68) 
 1 0.77 (0.70, 0.82) 0.60 (0.22, 0.68) 0.62 (0.29, 0.69) 
 1.5 0.75 (0.59, 0.80) 0.59 (-0.05, 0.70) 0.59 (0.06, 0.67) 
4 0 0.87  0.75  0.68  
 0.5 0.87 (0.83, 0.90) 0.77 (0.67, 0.84) 0.67 (0.50, 0.77) 
 1 0.87 (0.77, 0.90) 0.77 (0.51, 0.86) 0.69 (0.19, 0.83) 
 1.5 0.85 (0.68, 0.90) 0.75 (0.25, 0.86) 0.69 (0.01, 0.84) 
6 0 0.89  0.82  0.74  
 0.5 0.89 (0.85, 0.92) 0.80 (0.69, 0.87) 0.74 (0.58, 0.83) 
 1 0.89 (0.79, 0.93) 0.81 (0.55, 0.89) 0.74 (0.41, 0.87) 
 1.5 0.88 (0.71, 0.93) 0.81 (0.27, 0.91) 0.75 (0.16, 0.89) 
Note: Parameter estimates in the second column of Table 1 were used for predicting treatment benefits. 𝛿 = 0 
corresponds to the ideal situation when parameter estimates are equal to the true model parameters, in which case 
there is only one 𝐶𝑡+ℎ. For 𝛿 > 0, each entry in the table gives the median (minimum, maximum) of 64 (=2
6) values 
of 𝐶𝑡+ℎ corresponding to different combinations of parameter values that are at a distance of 𝛿 standard errors from 
their corresponding estimates. Each value of 𝐶𝑡+ℎ  was computed using 1,000 simulated new patients who were 
cannabis users.  
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Minimal correlations were observed when only baseline data were used for predictions (𝑡 =  0). When 
prediction origin 𝑡 ≥ 1, relatively high correlations between the predicted benefits and the corresponding 
true benefits were observed, especially when the parameter estimates were at a distance of 1 standard error 
or less (𝛿 ≤ 1) from their corresponding true parameters (see Supporting Information for results at 𝑡 = 1, 
3, and 5). This is most apparent if parameter estimates are the same as the true model parameters (𝛿 = 0). 
When parameter estimates moved further away from the true parameter values, that is as 𝛿 grew, the range 
of possible correlations grew wider, as expected. However, the median of the correlations stayed 
approximately the same as for 𝛿 = 0. The correlations were relatively high for retrospective predictions not 
only when predicting the benefits achieved up to the current week (ℎ = 0) but also for predictions of past 
benefits (ℎ < 0). Correlations for prospective predictions (ℎ > 0) were slightly lower than those for 
retrospective predictions with comparable 𝑡 and 𝛿 but still above 0.5, indicating a relatively reliable 
forecasting of future treatment benefits with a prediction horizon of 4 weeks or less, especially when 𝛿 ≤
1. 
 
1.3.5 Evaluation of benefit prediction in simulated new patients using relative biases (𝓑𝒕+𝒉) 
To further examine the performance of Formula (3), we assessed the biases of the predicted benefits 
relative to the true benefits. Each 𝓑𝒕+𝒉 was calculated from 1,000 simulated new cannabis users, and the 
results are shown in Table 5. Negative signs indicate that the predicted benefits are smaller than the true 
benefits. In general, when predicting the benefits for a given time point, the relative bias 𝓑𝒕+𝒉 decreased as 
the prediction origin (𝑡) increased, indicating that the more data we can use the less biased the prediction. 
For 𝑡 > 0 and 𝛿 ≤ 1, the 𝓑𝒕+𝒉 were relatively small, suggesting accurate predictions of past, current and 
future benefits when the patient provides at least one post-treatment response measure, even if the parameter 
estimates somewhat differ from their corresponding true parameter values. As expected, the range of 
possible values of 𝓑𝒕+𝒉 became wider as 𝛿 increased. However, the median of 𝓑𝒕+𝒉 stayed approximately 
the same as for  𝛿 = 0.  
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Table 5. Relative biases (ℬ𝑡+ℎ) of empirical Bayesian predictions of antipsychotic treatment benefits in 
simulated new patients who are cannabis users, by prediction origin (𝑡), prediction horizon (ℎ) and distance 
of parameter estimates from true parameters in standard error units (𝛿).  
  𝑡 + ℎ (weeks) 
𝑡 (weeks) 𝛿 2 4 6 
0 0 8.6  24.4  17.6  
 0.5 10.1 (-8.1, 36.3) 25.1 (8.3, 48.9) 16.9 (7.2, 33.8) 
 1 10.2 (-20.3, 82.1) 25.3 (-0.8, 82.7) 17.4 (1.0, 65.7) 
 1.5 9.5 (-29.2, 156.3) 25.9 (-7.5, 139.2) 16.5 (-2.3, 111.4) 
2 0 -7.0  -4.2 2.7  
 0.5 -5.9 (-10.5, 1.0) -2.9 (-10.9, 8.7) 3.3 (-4.3, 16.1) 
 1 -4.9 (-10.8, 5.8) -3.8 (-16.4, 25.8) 3.7 (-8.7, 40.8) 
 1.5 -4.6 (-12.8, 26.8) -2.1 (-23.7, 56.4) 3.8 (-13.3, 78.0) 
4 0 0.7  -1.3   -1.0  
 0.5 -0.5 (-5.4, 7.0) -1.4 (-5.8, 3.7) -1.0 (-8.0, 8.2) 
 1 -0.4 (-9.6, 18.8) -1.1 (-8.2, 13.7) -1.2 (-14.5, 27.1) 
 1.5 0.2 (-13.6, 42.6) -0.9 (-11.9, 35.6) -1.2 (-22.1, 60.3) 
6 0 0.4 -1.0  -1.6  
 0.5 0.1 (-7.4, 11.1) -0.3 (-4.4, 5.7) -1.2 (-5.4, 6.0) 
 1 0.2 (-12.6, 31.7) -0.4 (-6.4, 12.5) -1.3 (-9.8, 19.8) 
 1.5 -0.7 (-25.4, 63.1) 0.3 (-10.2, 28.0) -1.1 (-14.3, 46.7) 
Note: Parameter estimates in the second column of Table 1 were used for predicting treatment benefits. 𝛿 = 0 
corresponds to the ideal situation when parameter estimates are equal to the true model parameters, in which case 
there is only one ℬ𝑡+ℎ. For 𝛿 > 0, each entry in the table gives the median (minimum, maximum) of 64 (=2
6) values 
of ℬ𝑡+ℎ corresponding to different combinations of parameter values that are at a distance of 𝛿 standard errors from 
their corresponding estimates. Each value of ℬ𝑡+ℎ  was computed using 1,000 simulated new patients who were 
cannabis users.  
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Figure 1. Histograms of retrospectively-predicted antipsychotic treatment benefits at weeks 1 through 6 for 
the 55 non-cannabis users and 62 cannabis users in the pragmatic clinical trial. Benefits were predicted with 
the empirical Bayesian approach [Formula (3)]. (A), (C), (E), (G), (I) and (K) are predicted benefits for 
non-cannabis users at weeks 1, 2, 3, 4, 5 and 6, respectively; (B), (D), (F), (H), (J) and (L) are predicted 











Figure 2. Histograms of individual antipsychotic treatment benefits at weeks 1 through 6 from 1,000 
simulated non-cannabis users and 1,000 simulated cannabis users, assuming the model in Table 1. (A), (C), 
(E), (G), (I), and (K) are benefits for non-cannabis users at weeks 1, 2, 3, 4, 5, and 6, respectively; (B), (D), 











Figure 3. Comparison of estimators of medians of individual antipsychotic benefits at weeks 1 through 6. 
(A) Plots of medians of retrospectively predicted antipsychotic treatment benefits for the 55 non-cannabis 
users and 62 cannabis users from the pragmatic clinical trial, using the empirical Bayesian approach. (B) 
Medians of the individual benefits of 1,000 non-cannabis users and 1,000 cannabis users were simulated 
assuming the Model in Table 1. 
 
1.4. Discussion  
In this paper, we evaluated EB predictors of individual treatment benefits in the context of 
longitudinal binary outcomes which are frequent in medical research. Our results suggest that EB predictors 
accurately capture overall population trends in the achievement of individual benefits and show that EB 
predictors will reliably measure individual benefits in new patients both retrospectively and prospectively.  
Our approach utilizes EB predictors of individual random effects that are plugged into the formula 
defining benefit functions (Formula 3). The method is applicable to both 1-PM and 2-PM models (Diaz, 
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2016, 2019) and can be used to retrospectively evaluate patients’ responses from a RCT. It can also be used 
to retrospectively or prospectively predict individual benefits of different treatments in new patients with 
known characteristics and previous responses. Standard statistical packages implementing mixed-effects 
logistic models such as Stata (StataCorp LLC, College Station, TX) or SAS (SAS Institute Inc., Cary, NC) 
can be used to compute EB predictors.  
As an application, we used data from an antipsychotic RCT in patients with a first episode of non-
affective psychosis (Pelayo-Teran et al., 2014) and fitted a 1-PM model for the dichotomized disorganized 
dimension. Simulations showed that EB prediction of benefits was reliable, with small relative biases and 
relatively high correlations between predicted and true benefits, except when only baseline data are 
available for predictions.  
The present study confirmed cannabis use as a negative prognostic predictor for the disorganized 
dimension during antipsychotic treatment. Cannabis users were found to respond less and more slowly as 
compared to non-cannabis users based on individual benefit measurements, which is consistent with an 
analysis of the same data using a censored normal model of response trajectories that quantified only 
average cannabis effects (Pelayo-Teran et al., 2014). Our results support earlier findings that cannabis use 
is associated with more severe psychotic symptoms in patients with psychosis (Caspari, 1999; Foti et al., 
2010; Grech et al., 2005; Kuepper et al., 2011; Zammit et al., 2008).  
There is strong experimental evidence that cannabis use may cause psychotic symptoms 
(Bhattacharryya et al., 2009, 2012, 2015). In a carefully designed cross-over study, Bhattacharryya et al. 
(2015) randomized 36 healthy subjects to either the sequence of 10 mg of delta-9-tetrahydrocannabinol 
(delta-9-THC) and placebo or vice versa. The subjects did not have a personal or family history of mental 
illness, had minimal use of cannabis, alcohol or other psychotropic drugs and refrained from consuming 
caffeine, alcohol or tobacco during the study. Relative to placebo, the acute administration of delta-9-THC 
significantly induced the appearance of psychotic-like symptoms and anxiety (Bhattacharryya et al., 2015). 
This suggests that the reported associations between cannabis use and psychosis severity from observational 
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studies, or from experiments without randomization to cannabis or non-cannabis use, are not just the result 
of uncontrolled confounding factors. 
It is noteworthy that the 1-PM model with just a random intercept (and no interaction terms between 
cannabis and time or random effect for time) can show how the benefits evolve differently over the 
treatment period depending on patient characteristics, in this case cannabis use. This supports Diaz’s 
observation that individual benefit prediction reveals aspects of clinical phenomena that regression models 
alone cannot show (Diaz 2016, 2019). In this sense, it is a useful complement to standard regression 
analyses. In fact, we did not find any significant interaction between cannabis use and time when following 
the standard approach of testing the significance of the product of these two variables (data not shown).  
We were able to show, however, that cannabis use modified the effect of antipsychotic treatment in a time-
dependent way.  
At week 6 post-treatment, although the median individual benefits for cannabis users was 
comparable to that for non-cannabis users (Tables 2 and 3), there were more cannabis users without 
substantial treatment benefits (Figures 1 and 2). EB prediction makes it feasible to visualize the variation 
of treatment benefits among patients with different known characteristics as well as with the same known 
characteristics.  
We used correlations and relative biases to evaluate how well EB-predicted individual benefits 
measure true benefits (Tables 4 and 5). The correlations and relative biases were poor when only baseline 
data were available, which makes sense since the model did not include a random effect for time that was 
correlated with the intercept. Various 𝛿 values (0, 0.5, 1, and 1.5) were used to mimic the fact that the true 
parameter values may differ from the parameter estimates. As expected, the ranges for both correlations 
and relative biases became wider as 𝛿 increased (the less precise the estimators were, the less reliable 
predictions were). Nevertheless, the medians of correlations and relative biases remained stable, suggesting 
some robustness of EB benefit predictors to imprecise parameter estimation.  
The proposed method offers an excellent tool for analyzing clinical trials with binary outcomes that 
evolve over time. In the example application there were no variables in the model representing the three 
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different antipsychotics used in the trial because their effects did not significantly differ. The method, 
however, does allow inclusion of covariates representing treatment options. As such, it can be used to 
compare individual benefits for various treatments and help clinicians choose medications with the most 
promising benefits for new patients using patients’ characteristics and previous responses. Moreover, we 
can utilize existing software for computing EB predictors of random effects to predict individual benefits. 
This makes the application of this method more practical in clinical trial data analysis and potentially in 
medical practice.  
1.5. Limitations 
Our data do not allow completely establishing a causal relationship between cannabis and response 
to antipsychotics, because subjects were not randomized to cannabis or non-cannabis use. However, our 
results are consistent with other studies that show an association between cannabis use and increased risk 
of developing psychotic disorders as well as adverse outcomes in patients with psychosis (Linszen et al., 
1994; Moore et al., 2007; Zammit et al., 2008), and are consistent with experimental evidence of causality 
in this association (Bhattacharryya et al., 2009, 2012, 2015). 
In the application, we excluded 44 patients (26 non-cannabis and 18 cannabis users) whose 
disorganized dimension score at baseline was within the treatment target (≤ 3). More non-cannabis users 
were excluded, as expected, which could have potentially biased the regression results in favor of the null 
hypothesis of no difference between the two groups. Thus, if such bias occurred, the differences in 
antipsychotic benefits between the two populations may be greater than the differences observed in our 
patient sample. This, however, would not invalidate the model as a predictor of individual benefits in new 
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Chapter 2: Predicting individual benefits of medical treatments using longitudinal hospital data with 
non-ignorable missing responses caused by patient discharge 
In collaboration with Drs. Nikos Pantazis, Ph.D. and Francisco J. Diaz, Ph.D.  
(See collaborator affiliations in Acknowledgements) 
2.0. Abstract  
 We present a method for predicting individual treatment benefits with a novel 2-PM model that 
handles non-ignorable missingness due to hospital discharge and evaluate its reliability and accuracy by 
simulations. The longitudinal outcome of interest is modeled simultaneously with the hospital length of 
stay. The method was illustrated with an application assessing individual pain management benefits post 
spine fusion surgery, and the pain scores were pre-transformed with a discrete logit transformation. 
Empirical Bayes (EB) prediction was used to estimate patient level random effects. EB-Predicted individual 
benefits were compared with the Monte-Carlo computed benefits. To assess the prediction accuracy, we 
calculated Pearson’s correlation between the predicted and the true benefits as well as relative biases of the 
predicted benefits. Results showed that the EB-predicted individual benefits are close to Monte-Carlo 
computed ones. The prediction is reliable given that the parameter estimates are not far from the true 
parameter values. In summary, we proposed to use a 2-PM model with joint mixed effects to predict 
individual treatment benefits using unbalanced EHR data. This method will help to gain insights on 
treatment effects from real-world data.  
Keywords: individual benefits, Empirical Bayesian prediction, non-ignorable missingness, random effects, 
observational data  
33 
2.1. Introduction 
 It is increasingly recognized that a patient’s response to a medical treatment is a statistically 
heterogeneous phenomenon (de Leon, 2012). The average treatment effects may not represent a 
heterogeneous population of patients (Ruberg et al., 2010). The benefits each patient receive from the 
treatment could differ, requiring measurement of treatment benefits at the patient level (Diaz, 2016, 2019). 
Generalized linear mixed-effects models (Andrews and Cho, 2018; Botts et al., 2008; Cho 2017; Diaz, 
2016, 2019; Diaz et al., 2007, 2008, 2012a, 2012b, 2013a, 2013b, 2014; Senn, 2016; Zhu and Qu, 2016) 
allow identifying the various sources of variation of patients’ responses (Gewandter et al., 2019), offering 
an excellent tool for analyzing individual benefits. Diaz (2016, 2019) used 1-dimensional personalized 
medicine (1-PM) and 2-dimensional personalized medicine (2-PM) models to assess individual treatment 
benefits for clinical trial data using empirical Bayes (EB) predictors. The EB predictors of individual 
benefits are obtained using the EB predictor of the patient’s random effects as well as the estimated fixed 
effects. The EB predictor of the random effects is an estimate of the mean of the conditional distribution of 
the random effects given the patient’s data. 
 It is also increasingly recognized that real-world data (RWD) such as electronic health records 
(EHR) collected in a non-randomized setting hold critical value for clinical evidence generation and play a 
complementary role to clinical trial data (Miksad and Abernethy 2018). EHR data provide contextual details 
and longitudinal follow-up for patient’s outcomes. One limitation of the EHR data, however, is that there 
is usually incomplete follow-up due to hospital discharge. Since hospital discharge often depends on patient 
responses, the missing responses after discharge are nonignorable missing data (Little and Rubin 2002; 
Pantazis et al. 2010). This creates a problem for predicting treatment benefits because generalized mixed 
effects models assume missing at random (Hedeker and Gibbons, 2006; Laird 1998). When the missingness 
is non-ignorable, the analysis results can be seriously biased (Touloumi  et al. 1999).  
 Here, we propose to measure individual treatment benefits with hospital data by jointly modeling 
the patients’ responses to the medical treatment and hospital length of stay (LOS). Joint mixed-effects 
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models combining a generalized linear mixed effects model and a survival model have been used to handle 
longitudinal clinical trial data with informative drop-outs which produce non-ignorable missings 
(Schluchter 1992; De Gruttola and Tu 1994; Touloumi  et al. 1999; Pantazis et al. 2010; Crowther et al. 
2012;  Armero et al. 2018; Hickey  et al. 2018; Shardell and Ferrucci 2018; Schluchter and Piccorelli 2019; 
Papageorgiou et al. 2019). For example, Touloumi  et al. (1999) developed a method of parameter 
estimation for joint models that  combines restricted iterative generalized least-squares with a nested 
expectation-maximization algorithm. To our knowledge, these models have not been used to model hospital 
data, which are unavoidably biased by non-ignorable missingness due to discharge.   
 This study was motivated by the fact that many outcomes of clinical procedures, pharmacological 
therapies, or patient-reported outcomes measurements recorded in longitudinal EHR data are associated 
with hospital LOS. For instance, laboratory results such as biological markers of acute myocardial 
infarction (Gronski et al. 2012) or acute kidney injury (Edelstein 2008), as well as physical/behavioral 
scores (Shaw et al. 2018), are often measured only during hospital stay and are used in discharge planning 
and decision making. One example of patients’ self-reported measurements is pain scores post a surgical 
procedure, which are available before surgery or during the hospital stay after the surgery but are no longer 
recorded after discharge.  
 This study has three objectives. The first is to extend the methodology for predicting individual 
benefits in clinical trials (Diaz 2016, 2019) to predicting individual benefits using hospital data with non-
ignorable missingness. The second is to extend the definition of 2-PM models to joint mixed effects models 
that simultaneously represent the longitudinal patients’ outcome and the hospital LOS. The third is to 
evaluate the performance of the EB predictors of individual benefits based on joint mixed models using 
Pearson’s correlations between the predicted and the true benefits and the relative biases of the predicted 
benefits.   
2.2. Methods  
2.2.1. Joint model for observational longitudinal continuous outcomes with non-ignorable 
missingness  
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 Next we describe a joint multivariate random effects model to jointly model a continuous 
outcome and the hospital LOS. Suppose subject 𝑖 provided 𝑛𝑖 outcome measurements on days 𝑡1 < ⋯ <
𝑡𝑛𝑖 counted from treatment day 𝑡1 = 0 . Let 𝒚𝑖
∗ = (𝑦𝑖1, … , 𝑦𝑖𝑛𝑖)
𝑇
 be the outcome measurements, where 
𝑦𝑖1 is assumed to be measured before treatment and 𝑦𝑖𝑘  , 𝑘 ≥ 2  are measured after treatment. Let 𝒙𝑖𝑗 =
(𝑥𝑖𝑗,1, … , 𝑥𝑖𝑗,𝑝 )
𝑇
 and 𝒛𝑖𝑗 = (𝑧𝑖𝑗,1, … , 𝑧𝑖𝑗,𝑞 )
𝑇
be  vectors of covariates obtained at time 𝑡𝑗. A covariate can 
be time-independent (for instance, gender, race, etc.) or a known function of time (for instance, 𝑡, 𝑡2, etc.) 
The covariates in 𝒛𝑖𝑗 are usually a subset of the covariates in 𝒙𝑖𝑗. For subject 𝑖, the design matrix for the 
fixed and random effects of the outcome model are 𝑿𝑖
∗ = (𝒙𝑖,1, … , 𝒙𝑖,𝑛𝑖)
𝑇
 and 𝒁𝑖
∗ = (𝒛𝑖,1, … , 𝒛𝑖,𝑛𝑖)
𝑇
, 




∗ 𝜶𝑖 + 𝒆𝑖 
where  𝒚𝑖
∗ = (𝑦𝑖1, … , 𝑦𝑖𝑛𝑖)
𝑇
 is a vector containing the outcomes for subject 𝑖 in time order, 𝜷  is the 
vector of fixed regression coefficients,  𝜶𝑖 is the normally distributed vector of random effects with mean 
0, and 𝒆𝑖 is the vector of residuals for subject 𝑖 that are assumed to be independent between subjects and 




𝑑 be the hospital LOS in days. We assume that discharge always occurs after the last 
available outcome measurement, that is, 𝑡𝑛𝑖 < 𝑇𝑖
𝑑. Thus, if 𝑇𝑖
𝑑 was available in the EHR dataset and 𝑡𝑛𝑖 =
𝑇𝑖
𝑑  we add a small offset (i.e. 0.01 days) to make discharge time slightly larger than the last outcome 
measurement time. The discharge time is considered censored at 𝑡𝑛𝑖 + 0.01 if either 𝑇𝑖
𝑑   is missing in the 
dataset or if 𝑇𝑖
𝑑   is available but 𝑡𝑛𝑖 ≤ 𝑇𝑖
𝑑 − 1. 
 Let 𝒙𝑖
𝑑 = (1, 𝑥𝑖1
𝑑 , … , 𝑥𝑖𝑟
𝑑 )
𝑇
 be time-independent patient’s characteristics possibly related to LOS. 
The discharge time model is 
log(𝑇𝑖
𝑑) =  𝒙𝑖
𝑑𝑇 𝜷𝑑 + 𝑒𝑖
𝑑 ,  
where 𝜷𝑑 is a vector of fixed regression coefficients and 𝑒𝑖
𝑑~𝑁(0, 𝜎𝑑
2) is a residual. 
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The joint multivariate random effects model is 
𝒚𝒊 =  𝑿𝒊𝜷
𝑗 +  𝒁𝒊 𝜶𝑖
𝑗
+  𝜺𝑖,     









] , 𝜷𝑗 =  [
𝜷𝑑
𝜷










] , and 𝜺𝑖 =  [
𝒆𝑖
0
] .  
2.2.2. EB prediction of the random effects 
 The EB predictor of the random effects  𝜶𝑖
𝑗






where ?̂? is the estimator of 𝑫 = Var(𝒃𝑖
𝑗
), and 𝑽?̂?  is the estimator of 𝑽𝒊 = Var(𝒚𝑖) = 𝑹𝒊 + 𝒁𝒊𝑫𝒁𝒊
𝑻 with 









] is the estimated residuals for subject 𝑖. 
 The last row of ?̂?𝑖 is set to 0 during the calculation of the random effects because the error term of 
the LOS model (𝑒𝑖
𝑑) is already included in  𝜶𝑖
𝑗
. 
 The 1st element of  𝜶𝐸𝐵,𝑖
𝑗
 is the EB estimate of the LOS model residual for subject 𝑖. The other 
elements of 𝜶𝐸𝐵,𝑖
𝑗
 estimate  𝜶𝑖 and are denoted here by  ?̂?𝑖.  
2.2.3. Disease severity and individual benefits  
Individual treatment benefits can be predicted/estimated using the estimated model parameters, not 
only for the subjects in the analysis but also for simulated new patients. The severity of a patient’s outcome 
at a given time point is defined as the probability that the patient’s outcome is outside of the therapeutic 
target (Diaz, 2016). The disease severity for patient 𝑖 before treatment (time 0) is  
𝑠0,𝑖 =  1 −  Φ (
𝑐 − 𝒙𝑖1




where the therapeutic target is to achieve 𝑦 ≤ 𝑐.  
The post-treatment severity of the patient at time 𝑡 is  









  and 𝒛𝑖
(𝑡)
 are covariate values measured at time 𝑡.  
 The individual benefit of the treatment for patient 𝑖 after 𝑡 units of time is defined as the reduction 
in disease severity at time t from time 0 (Diaz, 2016, 2019), that is,  




)  = 𝑠0,𝑖 − 𝑠𝑡,𝑖.            (2) 
2.2.5. Empirical Bayesian prediction of benefits  
 As described in 2.2, the individual treatment benefit is defined as the decrease of the disease 
severity from baseline for the patient (Diaz 2019).  If ?̂?𝑖  is the EB predictor of the patient’s  𝒃𝒊, the EB 
predictor of the individual benefit at time 𝑡 ≥ 0 is   
𝑏 (𝑡; ?̂?, ?̂?𝑖, 𝒙𝑖
(𝑡), 𝒛𝑖





) −  Φ (
𝑐 − 𝒙𝑖1
𝑇 ?̂? − 𝒛𝑖1
𝑇 ?̂?𝑖
?̂?𝑒
)} × 100,          (3) 
where ?̂? is the maximum likelihood estimate of 𝜷 and ?̂?𝑒 is the maximum or restricted maximum likelihood 
estimate of the standard deviation of the pain score model residuals. 
2.2.4. Transformation of outcome variable. 
 Here we are concerned with outcomes that decrease over time and have a minimum value during 
the study.  If the outcome is continuous, we can use a logit transformation. If not, we can use a discrete 
logit transformation. For instance, if the outcome is in the range of 0 to m where m is the maximum value 
of the outcome. The following discrete logit transformation can be used to transform the discrete outcomes: 
𝑇(𝑦𝑖𝑗) = log  (
𝑦𝑖𝑗 + 1
𝑚 + 1 −  𝑦𝑖𝑗
)    (4) 
where 𝑦𝑖𝑗  is the outcome for subject 𝑖 at time j.  
  
2.2.5. Application  
In this study, we used EHR data from the Cerner HealthFacts® dataset (Cerner HealthFacts®; 
Kansas City, MO).  The Cerner HealthFacts dataset is a deidentified EHR database, and this study 
exempted from institutional review by Western IRB (Olympia, WA).  Adult patients undergoing spine 
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fusion surgery as inpatients in the United States between January 1, 2014 and December 31, 2015 were 
selected using International Classification of Diseases ICD-9 codes 81.00 to 81.08 and corresponding 
ICD-10 codes for spine fusion. Additional inclusion criteria were 1) patients with at least one pain score 
available on the day of surgery (day 0) and at least one pain score post-surgery; 2) the maximum baseline 
pain score was at least 7; and 3) patients had 1 to 5 days of post-surgical hospital stay. Patients without at 
least 6 months of records in the database prior to the surgery were excluded. We identified 940 patients 
who satisfied the inclusion criteria and the 330 patients from the hospital with the largest number of 
patients were selected as the subjects for this study to obtain greater homogeneity since each hospital may 
have different pain management protocols. 
In the application, the outcome is maximum daily pain score post spine fusion surgery. The pain 
scores are patient-reported measurements that ranged from 0 to 10, with 0 indicating no pain and 10 
indicating the most severe pain. The outcome of interest is the patient’s maximum daily pain score, 
obtained at day 0 and during the 1-5 days of post-surgical hospital stay.  In most cases, patients last pain 
score was observed on the day of the discharge. In a few cases, patients’ pain score measurement was 
deaminated before the day of discharge. In these few cases, the outcome was considered censored on the 
day of the last pain score measurement. An offset of 0.01 was added to the LOS and censoring time to 
make them slightly larger than the time of the last pain scores. We used the jmre1 (Pantazis et al. 2010) 
command in Stata (StataCorp LLC, College Station, TX) for this analysis.  
 In the pain score model, the design matrix for the fixed effects is  
𝑿𝑖
∗ =  [𝟏 𝑋𝑖1 𝑋𝑖2 𝒕𝑖 𝑋𝑖3] 
where 𝑥𝑖1, 𝑥𝑖2 denote the dichotomous variables Elderly (1 if age>65, 0 otherwise) and Depression (1 if 
the patient had a record of preoperative depression diagnosis, 0 otherwise), respectively. 𝑋𝑖1 =
(𝑥𝑖1, … , 𝑥𝑖1)
𝑇 , 𝑋𝑖2 = (𝑥𝑖2, … , 𝑥𝑖2)
𝑇, 𝒕𝑖 = (𝑡𝑖1, … , 𝑡𝑖𝑛𝑖)
𝑇
 is the vector containing the days from surgery on 
which the pain scores were observed for subject 𝑖, and  𝑋𝑖3 = (𝑥𝑖2𝑡𝑖1, … , 𝑥𝑖2𝑡𝑖𝑛𝑖)
𝑇
 is the interaction 
between Depression and time. 
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 In the LOS model, the design vector 𝒙𝑖
𝑑 =  [1 𝑥𝑖1 𝑥𝑖2] , where 𝑥𝑖1, 𝑥𝑖2 are Elderly and 
Depression variables, respectively.  
 The maximum daily pain score is 10, that is m=10 in formula (3).  The discrete logit 
transformation we used for pain scores is 
log  (
y𝑖𝑗 + 1
11 −   𝑦𝑖𝑗
) 
where 𝑦𝑖  is the maximum daily pain score for subject 𝑖 at Day𝑖𝑗. The distribution of the original pain 
scores are highly skewed with higher frequencies for severe pain scores. After this transformation, the 
distributions of the EB predictor of the LOS model residuals and the random intercept and the random 
effect of time for the pain score model were relatively normal, suggesting good model fit. 
 The postoperative treatment target was defined as a maximum pain score level of 6 or lower, 
which corresponds to a transformed pain score of 𝑐 = 𝑇(6) = 0.3365 or lower.  
 𝜶𝐸𝐵,𝑖
𝑗
 was calculated using the Stata “predict” command after running the jmre1 command. 
2.2.6. Monte Carlo computation of individual benefits based on patients’ characteristics 
 As an alternative approach to analyze the pain management benefits, Monte Carlo computation was 
used to estimate the quartiles of the probability distribution of individual benefits for the four 
subpopulations by time (Table 3) using the algorithm below.   
1. Draw 1000 random effects for each group of patients (depending on age and depression) from the 
distribution of the random effects 
2. Generate random coefficients of the intercept and the time for the 1000 patients in each group by 
adding up the fixed effects and the random effects for the intercept and time, respectively 
3. Calculate benefits for each patient on days 1 through 5 post-surgery using the benefit function by 
plugging in the therapeutic target of the transformed pain score, age, depression, the random 
coefficients, days post-surgery, and the variance of the pain score model residuals 
4. Calculate median, p25, p75 for days 1 through 5 post-surgery for the 4 groups  
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2.2.7. Simulations to evaluate the performance of individual benefit predictions in hypothetical new 
patients 
 To evaluate how well the proposed method of benefit prediction would work in new patients, we 
assessed the predicted benefits through simulations for various prediction origins (𝑡), prediction horizons 
(ℎ) and distance of parameter estimates from true parameters (𝛿) in standard error units (Diaz 2019) 
(Tables 4 and 5). 
 The performance of the predictions was assessed using the approach used by Diaz (2019). Pearson’s 
correlation (𝐶𝑡+ℎ) was used to examine the correlation between the predicted benefits and the simulated 
true benefits. Each value of 𝐶𝑡+ℎ was computed with a simulated sample of 1000 new patients. The accuracy 
of the prediction was also assessed using relative bias (Diaz, 2019). Briefly, the bias was defined as the 
predicted benefit minus the true benefit for each simulated patient at each time point, and the relative bias 
(ℬ𝑡+ℎ) was defined as {(mean of bias) / (mean of true benefit)} x 100 for each set of 1,000 simulated 
patients. 
 Simulations of the true and predicted benefits were carried out with the algorithm described below. 
1. Define values of the distance 𝛿 between the parameter estimates in Table 1 and the true 
parameters, prediction origin 𝑡, prediction horizon ℎ, age, and depression. Since t=0 represents 
baseline, and we also need a row for the drop-out model, a total of t+2 simulated responses are 
needed. 
2. Obtain the estimates of both the vector of fixed effects and the variance of the random intercept 
from Table 1.  
3. Calculate the true fixed effects for the pain score model and the true variance/covariance matrix 
of the random effects based on 𝛿. For instance, 𝛿 = 0.5 indicates each true parameter value is 
± 0.5 times standard errors (SE) away from the corresponding parameter estimate of the model 
(Column 2 of Table 1). Hence, for 12 parameters, there are 212 =  4096 sets of true parameter 
values for a particular 𝛿 > 0 (Diaz, 2019).  
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4. For SE of principle minor and determinant of D, multiply the estimates of principle minor and 
determinant by 0.6 and use as proxies for the SE. 
5. Obtain the design matrix of dimension (𝑡 + 2) × 8  corresponding to the fixed effects. Also 
obtain the design matrix of dimension (𝑡 + 2) × 3  corresponding to the random effects.  
6. Draw 1,000 random effects from a joint normal distribution with mean 0 and variance/covariance 
matrix D equal to the true variance calculated at step 4. These represent 1,000 new patients. Draw 
t+1 of error terms for each of the 1,000 patients. 
7. Calculate the true benefits using the benefit formula (3), the true fixed effects from step #3, the 
simulated true random effect, and the errors from step 6. 
8. Obtain EB predictors for the random effects using matrix calculation for the 1,000 new patients. 
9. Calculate the predicted benefits using the benefit formula, the fixed effects from Table 1 and 
predicted random effects for the pain score model from step 8. 
2.3. Results  
2.3.1. The association between pain scores and LOS and the impact of depression and age on 
individual postoperative pain management   
 The joint model (Table 3) showed a positive covariance between the random residual of the LOS 
model and the random intercept of the pain score model (0.4985), between the random residual of the LOS 
model and the random effect of time in the pain score model (0.6631), as well as between the random 
intercept and the random effect of time in the pain score model (0.8471).  Log-likelihood ratio test 
comparing the full model and the constrained model (setting the covariance between the random residual 
of the LOS model and the random intercept or the random effect of time of the pain score model) indicated 
that the association between the pain score model and the LOS model was significant (p = 1.697e-22). 
 As shown in Table 3, the preoperative depression comorbidity was significantly associated with 
higher pain scores at baseline on average (parameter estimate = 0.2278) whereas older age was significantly 
associated with lower baseline pain scores (parameter estimate = -0.1853). The interaction between 
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depression and time is positive (parameter estimate=0.1327), indicating that the slope of the decrease in 
pain scores overtime is less steep for patients with depression.  
 For the LOS model, older age was significantly associated with longer post-surgical LOS 
(parameter estimate = 0.2196), and preoperative depression comorbidity tended to have slightly longer LOS 
(parameter estimate = 0.0886). 
2.3.2. Comparison of Empirical Bayesian quartile estimates with Monte Carlo estimates of individual 
benefits  
We first analyzed the EB predicted individual pain management benefits in the 330 subjects during 
the study using formula (4). The medians and the first and third quartiles of the predicted benefits are shown 
in Table 2. During the 5 days’ recovery post the surgery, all four groups of patients gradually received more 
benefits in pain management over time. For the same time points, how much benefits each subject received 
differ depending on the patient’s preoperative depression status and age. The degree of variations in the 
amount of benefits within the same subgroup defined by depression and age also differ depending on the 
group and time points.   For instance, in elderly patients with no depression, the median decrease in disease 
severity was 25.5% probability units compared to 12.1% for patients in the same age group with depression 
at day 1. The minimum and maximum benefits for elderly patients with no depression at day 1 were 4.4% 
and 34.2%, respectively, whereas for patients in the same age group with depression these were 3.5% and 
19.1%, respectively. Similar effects of depression were observed in younger patients. The effects of age 
were more apparent in patients with depression, with younger patients showing lower median as well as 
minimum benefits at earlier time points.   
 As an alternative approach to analyze the pain management benefits, Monte Carlo computation was 
used to estimate the quartiles of the probability distribution of individual benefits for the four 
subpopulations (Table 3). The random effects (random residuals of the LOS model, random intercept and 
random slope of the pain score model) were simulated from a joint normal distribution with mean 0 and 
variance/covariance matrix (Table 1). The treatment benefits were calculated for the four subpopulations 
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at days 1 through 5 with formula (4), using the estimated values of the fixed effects shown in Table 1 in 
place of 𝜷. 
 To visualize how the medians of the predicted pain management benefits changed over time post-
surgery for the four groups of subjects in the study and compare the patterns with the Monte-Carlo 
computed benefits, we plotted the medians in Tables 3 and 4 in Panels A and B of Figure 1, respectively. 
Separate plots (Figure 2) were also made for each of the four groups, comparing EB-predicted and Monte-
Carlo calculated benefits. The medians of benefits for patients increase at a slower pace for patients with 
depression compared to patients without depression in the same age group. In patients with no depression, 
the effects of age on the medians of benefits are minimal. In patients with depression, however, younger 
age was associated with slightly lower medians of benefits in earlier days post-surgery. The patterns for 
EB-predicted benefits are consistent with the Monte-Carlo computed benefits (Figures 1 and 2), suggesting 
that the medians of EB predictions, which are less computationally demanding than medians based on 
simulations, are good estimators of median benefits.  
2.3.3. Evaluation of benefit prediction in simulated new patients using correlations between 
predictions and true benefits  
 Correlations between the predicted individual benefits and the true individual benefits in simulated 
new patients were analyzed the using Pearson’s correlations (𝐶𝑡+ℎ). Each 𝐶𝑡+ℎ was calculated from 1000 
simulated patients in each of the four subpopulations defined by age and depression categories. Results for 
younger patients without depression are shown in Table 4. Results for the other three groups are included 
in the Supporting Information. Minimal correlations were observed when only baseline data were used for 
predictions (prediction origin 𝑡 =  0). Correlations increased as t increased. This is true for predicting 
benefits for a given day (i.e., day 2 post-surgery) as well as predicting benefits for the same day (h=0), 
which is most apparent if the parameter estimates are the same as the true model parameters (𝛿 = 0). When 
parameter estimates moved further away from the true parameter values in the model, that is, as 𝛿 increased, 
the range of correlation values grew wider, as expected. However, the median of the correlations stayed 
approximately the same as for 𝛿 = 0. When 𝛿 was sufficiently small and t was sufficiently large, the 
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correlations were good for the predictions not only when predicting the benefits achieved up to the current 
week (ℎ = 0) but also for predictions of past benefits (ℎ < 0). For predicting future benefits, correlations 
decreased as h increased, which is especially true for small t (i.e., t <2).  
 
2.3.4. Evaluation of benefit prediction in simulated new patients using relative biases (𝓑𝒕+𝒉) 
 To further evaluate the performance of the benefit predictor, we assessed the biases of the predicted 
benefits relative to the true benefits as defined in the Methods section. Each 𝓑𝒕+𝒉 was calculated from 1000 
simulated patients for each of the four subpopulations, and the results for younger patients without 
depression are shown in Table 5. The negative signs indicate that the predicted benefits are smaller than 
the true benefits. Higher relative biases were observed when t=0. 𝓑𝒕+𝒉 decreased as t increased. This is true 
for predicting benefits for a given day (i.e., day 2 post-surgery) as well as predicting benefits for the same 
day (h=0), indicating that the more data we can use the less biased the prediction will be. When 𝛿  is 
sufficiently small, relative biases were relatively small when t > 0, suggesting relatively accurate predictions 
of past, current and future benefits when the patient provides at least one measure of the pain scores post-
surgery. As expected, the range of possible values of 𝓑𝒕+𝒉 became wider as the 𝛿 increased. However, the 
median of 𝓑𝒕+𝒉 stayed approximately the same as for  𝛿 = 0.  
 





Fixed effects for LOS (days)   
LOS intercept 0.2465 (0.0385) <0.0001 
Older agea 0.2196 (0.0644) 0.001 
Depressionb 0.0886 (0.0532) 0.096 
Fixed effects for transformed pain score   
Pain score intercept 1.4704 (0.0544) <0.0001 
Older agea -0.1853 (0.0931) 0.047 
45 
Depressionb 0.2278 (0.0742) 0.001 
Time (days)c -0.6771 (0.0461) <0.0001 
Interaction between depression and time 
0.1327 (0.0662) 0.045 
Variance of random effects   
LOS residual, 𝑑11 0.2281  -- 
Pain score intercept, 𝑑22 0.1384 
-- 
Timeb, 𝑑33 0.0916 
-- 
Covariances   
 
Cov (LOS residual, Pain score intercept),  𝑑12 0.4985 
-- 
Cov (LOS residual, Time),  𝑑13 0.6631 
-- 
Cov (Pain score intercept, Time), 𝑑23 0.8471 
-- 
Residual variance,  σ2 0.3835 -- 
SE: standard error. 
aThe dichotomous covariate was defined as 1 if the age of the subject was greater than 65, and 0 otherwise.  
bThe dichotomous covariate depression was defined as 1 if the subject had a record of depression diagnosis, and 0 
otherwise.  
cTime was defined as days post spine fusion surgery.  
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Table 2. Sample medians (and first and third quartiles) of individual benefits (x100) of postoperative pain 
management on days 1 through 5 for 330 subjects after spine fusion.  Empirical Bayesian predictors of the 
subject’s random effects were used for predicting treatment benefits, combining data with parameter 
estimates in Table 1.  
 
Study group Day 1 Day 2 Day 3 Day 4 Day 5 
Age ≤ 65, 
 no depression 
(N=191) 
18.6 




 (70.9, 91.8) 
93.0 
 (87.3, 95.5) 
94.4 
(89.7, 97.0) 












 (57.2, 96.9) 
Age > 65, 
 no depression 
(N=49) 
25.5 
 (4.4, 34.2) 
64.2 
 (15.4, 76.3) 
87.6 
 (34.6, 89.4) 
89.4 
 (58.3, 93.3) 
90.4 
(76.2, 93.8) 















Table 3. Estimates of medians (and first and third quartiles) of individual benefits (x100) of postoperative 
pain management on days 1 through 5 after spine fusion, obtained with Monte Carlo computation.  The 
model in Table 1 was used for simulating 1,000 patients for each study group.   
 
Study group Day 1 Day 2 Day 3 Day 4 Day 5 
Age ≤ 65, 
no depression 
18.5 




 (49.2, 90.6) 
89.5 
 (72.1, 94.4) 
92.4 
(82.0, 96.3) 











 (51.1, 96.7) 
Age > 65, 
no depression  
25.1 
 (8.9, 46.2) 
63.7 
 (30.3, 77.6) 
80.1 
 (56.3, 87.8) 
86.0 
 (71.7, 92.1) 
88.9 
(78.2, 93.8) 















Table 4. Pearson correlations (𝐶𝑡+ℎ) between empirical Bayesian predicted benefits and true 
benefits of postoperative pain management on days 1, 3, 5 in simulated new patients who are 
under 65 and with no depression, by prediction origin (𝑡), prediction horizon (ℎ) and distance of 
parameter estimates from true parameters in standard error units (𝛿).  
 
  𝑡 + ℎ (weeks) 
𝑡 (𝑤𝑒𝑒𝑘𝑠)  𝛿 1 2 3 4 5 
0 0 0.51  0.38 0.31  0.22  0.02 
 0.2 0.45 (0.32, 0.56) 0.41 (0.25, 0.54) 0.34 (0.15, 0.50) 0.21 (0.04, 0.37) 0.00 (-0.02, 0.27) 
 0.4 0.42 (0.16, 0.61) 0.36 (0.09, 0.56) 0.28 (-0.01, 0.52) 0.15 (-0.07, 0.40) 0.01 (-0.24, 0.38) 
 0.8 0.31 (-0.28, 0.64) 0.22 (-0.37, 0.60) 0.12 (-0.32, 0.55) 0.05 (-0.14, 0.41) 0.06 (-0.28, 0.55) 
 1.2 0.17 (-0.45, 0.65) 0.09 (-0.55, 0.62) 
-0.02 (-0.40, 
0.57) 
0.03 (-0.14, 0.47) 0.08 (-0.30, 0.57) 
1 0 0.69 0.69 0.63  0.59 0.42 
 0.2 0.73 (0.62, 0.82) 0.69 (0.54, 0.79) 0.63 (0.45, 0.77) 0.54 (0.33, 0.68) 0.43 (0.19, 0.60) 
 0.4 0.73 (0.49, 0.84) 0.68 (0.42, 0.82) 0.58 (0.29, 0.77) 0.49 (0.13, 0.71) 0.37 (0.01, 0.64) 
 0.8 0.76 (0.02, 0.90) 0.70 (-0.17, 0.87) 0.61 (-0.24, 0.80) 0.47 (-0.18, 0.73) 0.35 (-0.10, 0.65) 
 1.2 0.80 (-0.24, 0.93) 0.75 (-0.39, 0.89) 0.66 (-0.35, 0.82) 0.54 (-0.18, 0.76) 0.43 (-0.15, 0.70) 
2 0 0.87  0.84 0.80 0.76 0.70 
 0.2 0.87 (0.78, 0.93) 0.84 (0.78, 0.91) 0.80 (0.67, 0.88) 0.75 (0.57, 0.85) 0.69 (0.47, 0.81) 
 0.4 0.88 (0.69, 0.94) 0.84 (0.63, 092) 0.79 (0.53, 0.89) 0.71 (0.31, 0.86) 0.64 (0.20, 0.83) 
 0.8 0.91 (0.28, 0.96) 0.88 (0.04, 0.94) 0.81 (-0.14, 0.91) 0.72 (-0.11, 0.88) 0.64 (-0.03, 0.86) 
 1.2 0.88 (0.06, 0.96) 0.84 (-0.10, 0.94) 0.77 (-0.14, 0.92) 0.69 (-0.11, 0.90) 0.62 (-0.09, 0.88) 
3 0 0.93 0.92 0.89 0.88  0.83 
 0.2 0.93 (0.87, 0.96) 0.91 (0.86, 0.95) 0.89 (0.80, 0.94) 0.86 (0.73, 0.93) 0.82 (0.66, 0.90) 
 0.4 0.93 (0.79, 0.97) 0.92 (0.79, 0.96) 0.89 (0.67, 0.95) 0.85 (0.50, 0.93) 0.80 (0.35, 0.92) 
 0.8 0.90 (0.30, 0.97) 0.90 (0.30, 0.96) 0.86 (0.05, 0.95) 0.81 (-0.03, 0.94) 0.76 (0.02, 0.93) 
 1.2 0.89 (0.17, 0.98) 0.89 (0.33, 0.97) 0.84 (0.11, 0.96) 0.77 (0.01, 0.95) 0.71 (-0.01, 0.93) 
4 0 0.95 0.95 0.94 0.92 0.90 
 0.2 0.95 (0.91, 0.97) 0.95 (0.90, 0.97) 0.93 (0.87, 0.96) 0.91 (0.83, 0.96) 0.89 (0.76, 0.95) 
 0.4 0.94 (0.84, 0.98) 0.95 (0.87, 0.97) 0.93 (0.77, 0.97) 0.90 (0.60, 0.96) 0.88 (0.46, 0.95) 
 0.8 0.89 (0.28, 0.98) 0.92 (0.49, 0.98) 0.90 (0.20, 0.97) 0.86 (0.15, 0.97) 0.82 (0.00, 0.96) 
 1.2 0.86 (0.06, 0.99) 0.90 (0.54, 0.98) 0.88 (0.27, 0.97) 0.84 (0.19, 0.97) 0.80 (-0.04, 0.96) 
5 0 0.96 0.96 0.96 0.95 0.93 
 0.2 0.96 (0.93, 0.98) 0.97 (0.93, 0.98) 0.96 (0.91, 0.98) 0.94 (0.86, 0.97) 0.93 (0.81, 0.97) 
 0.4 0.94 (0.87, 0.98) 0.96 (0.89, 0.98) 0.95 (0.82, 0.98) 0.93 (066, 0.98) 0.91 (0.56, 0.97) 
 0.8 0.88 (0.19, 0.99) 0.94 (0.62, 0.99) 0.93 (0.44, 0.98) 0.90 (0.25, 0.98) 0.86 (-0.02, 0.98) 
 1.2 0.83 (-0.02, 0.99) 0.90 (-0.57, 0.99) 0.89 (0.40, 0.98) 0.87 (0.31, 0.98) 0.84 (0.106,0.97) 
Note: Parameter estimates in the second column of Table 1 were used for predicting treatment benefits. 𝛿 = 0 
corresponds to the ideal situation when parameter estimates are equal to the true model parameters, in which case 
there is only one 𝐶𝑡+ℎ. For 𝛿 > 0, each entry in the table gives the median (minimum, maximum) of 4096 (=2
12) values 
of 𝐶𝑡+ℎ corresponding to different combinations of parameter values that are at a distance of 𝛿 standard errors from 
their corresponding estimates. Each value of 𝐶𝑡+ℎ  was computed using 1,000 simulated new patients who were 
cannabis users.  
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Table 5. Relative biases (ℬ𝑡+ℎ) of empirical Bayesian predictions of postoperative pain 
management benefits on days 1, 3, 5 in simulated new patients who are under 65 and with no 
depression, by prediction origin (𝑡), prediction horizon (ℎ) and distance of parameter estimates 
from true parameters in standard error units (𝛿).  
 
  𝑡 + ℎ (weeks) 
𝑡 (𝑤𝑒𝑒𝑘𝑠)  𝛿 1 2 3 4 5 
0 0 -13.5 13.8  25.0  24.6  20.5 
 0.2 -15.6 (-28.7, -1.7) 12.9 (3.9, 24.3) 25.0 (12.0, 39.5) 22.6 (10.6, 38.3) 18.6 (6.9, 33.5) 
 0.4 -16.1 (-35.5, 7.9) 14.2 (-1.9, 28.8) 30.2 (3.5, 50.3) 29.1 (3.7, 52.5) 24.9 (3.4, 50.0) 
 0.8 -20.6 (-47.8,41.3) 18.2 (-10.8, 40.9) 42.4 (-5.2, 74.4) 44.9 (-0.7, 82.4) 41.0 (-0.1, 78.0) 
 1.2 -26.7 (-55.2,97.9) 22.3 (-14.1, 60.8) 53.4 (-4.6, 99.4) 58.0 (1.4, 123.4) 55.2 (2.9,117.6) 
1 0 -9.4  9.8  14.5  13.8  11.0 
 0.2 -9.0 (-20.2, 2.6) 7.7 (0.0, 16.3) 15.3 (5.8, 26.3) 15.8 (5.4, 27.4) 13.5 (4.6, 25.9) 
 0.4 -8.9 (-26.7, 11.8) 8.4 (-3.8, 11.0) 18.3 (-1.0, 33.4) 20.1 (0.0, 36.3) 19.0 (0.5, 38.8) 
 0.8 -12.3 (-35.0,37.1) 10.0 (-10.4, 29.4) 24.8 (-8.2, 49.5) 22.9 (-3.4, 61.4) 30.6 (-0.5, 57.5) 
 1.2 -17.5 (-40.1,76.7) 10.9 (-10.7, 40.0) 28.2 (-7.4, 59.4) 35.8 (-1.8, 17.9) 38.8 (1.5, 71.5) 
2 0 -4.5  4.3  9.9  9.0  8.5 
 0.2 -4.5 (-12.4, 3.5) 4.0 (-1.5, 9.9) 8.1 (1.8, 13.1) 9.0 (2.7, 16.6) 8.5 (2.2, 16.3) 
 0.4 -3.8 (-16.8, 8.8) 3.7 (-4.2, 13.3) 9.0 (-2.9, 16.0) 11.2 (-1.0, 19.4) 11.6 (-0.2, 21.5) 
 0.8 -5.9 (-28.3, 29.5) 2.9 (-14.0, 21.2) 9.8 (-6.5, 29.7) 13.3 (-1.7, 35.0) 14.8 (-0.2, 35.9) 
 1.2 -10.5 (-47.4,62.7) 1.2 (-34.9, 27.8) 9.8 (-27.6, 36.7) 13.7 (-22.5, 42.5) 15.3 (-21.0, 47.0) 
3 0 -3.6  1.4  5.0  4.0  4.5 
 0.2 -2.1 (-8.5, 5.4) 2.0 (-2.7, 8.3) 4.1 (0.9, 7.6) 4.9 (1.0, 8.8) 5.0 (1.0, 9.5) 
 0.4 -1.0 (-13.8, 8.9) 1.4 (-7.3, 9.6) 3.8 (-2.3,11.2) 5.1 (-0.9, 11.9) 5.9 (-0.4, 12.5) 
 0.8 -3.6 (-31.4, 27.4) -0.9 (-23.7, 17.0) 3.3 (-17.7, 18.8) 5.6 (-12.8, 23.2) 6.6 (-11.0, 25.3) 
 1.2 -8.3 (-57.2, 64.4) -4.7 (-47.5, 27.5) 1.1 (-42.8, 23.8) 4.5 (-39.2, 27.4) 6.3 (-37.0, 34.1) 
4 0 0.7 1.3  2.1  3.4  2.9 
 0.2 -0.8 (-6.6, 5.6) 1.0 (-4.5, 5.7) 2.2 (-1.4, 5.8) 2.6 (0.0, 6.0) 2.8 (0.6, 5.7) 
 0.4 0.0 (-13.4, 10.3) 0.2 (-9.8, 9.6) 1.6 (-6.4, 8.0) 2.3 (-4.0, 9.2) 2.7 (-2.8, 10.0) 
 0.8 -3.1 (-34.0, 28.0) -3.2 (-27.4, 15.9) -0.3 (-23.8, 12.6) 1.9 (-21.3, 15.3) 3.0 (-18.7, 16.6) 
 1.2 -7.9 (-61.1, 66.3) -8.8 (-54.6, 23.7) -4.8 (-49.1, 19.1) -1.9 (-46.2, 18.6) -0.1 (-45.2, 22.3) 
5 0 0.0  0.7  1.2  1.5  2.1 
 0.2 -0.3 (-0.9, 5.7) 0.5 (-5.3, 5.5) 1.2 (-2.9, 4.8) 1.6 (-1.7, 4.9) 1.7 (-1.2, 4.4) 
 0.4 0.1 (-12.7, 11.1) -0.4 (-12.1, 8.8) 0.4 (-9.1, 7.6) 1.1 (-6.9, 6.8) 1.5 (-5.4, 7.8) 
 0.8 -2.6 (-35.9, 31.1) -4.6 (-31.5, 14.8) -2.4 (-26.9, 11.5) -0.4 (-25.1, 10.6) 0.7 (-22.3, 12.1) 
 1.2 -7.9 (-63.6, 72.1) -11.3 (-57.3,23.2) -8.1 (-52.8, 17.6) -5.9 (-51.3, 15.5) -4.2 (-48.8, 17.5) 
Note: Parameter estimates in the second column of Table 1 were used for predicting treatment benefits. 𝛿 = 0 
corresponds to the ideal situation when parameter estimates are equal to the true model parameters, in which case 
there is only one ℬ𝑡+ℎ. For 𝛿 > 0, each entry in the table gives the median (minimum, maximum) of 4096 (=2
12) 
values of ℬ𝑡+ℎ corresponding to different combinations of parameter values that are at a distance of 𝛿 standard 
errors from their corresponding estimates. Each value of ℬ𝑡+ℎ  was computed using 1,000 simulated new patients 
who were cannabis users.  
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Figure 1. Comparison of estimators of medians of individual pain management benefits at days 1 through 
6. (A) Plots of medians of predicted antipsychotic treatment benefits for the 330 subjects in this study. (B) 
Medians of the individual benefits of 1,000 patients in each of the four groups were computed using Monte-





Figure 2. Comparisons of medians of empirical Bayes-predicted and Monte-Carlo computed antipsychotic 
treatment benefits for the four groups of patients. Medians of the empirical Bayes-predicted treatment 
benefits were calculated for the 330 subjects in this study, and medians of the Monte-Carlo computed 
benefits were calculated using 1,000 simulated patients for each of the four groups assuming the Model in 
Table 1. (A) Younger age with no depression. (B) Younger age with depression. (C) Older age with no 
depression. (D) Older age with depression.  
 
2.4. Discussion  
 In this paper, we extended the methods for individual treatment benefit prediction using mixed- 
effects models proposed by Diaz (2016, 2019) to allow non-ignorable missingness in the longitudinal data. 
Although modeling informative drop-out in the analysis of clinical trial data with some patients dropping 
out of the study after randomization is not new, the idea of extending this concept to real-world hospital 
data for which the follow-up data are incomplete due to hospital discharge is novel. This is the first paper 
to analyze individual treatment benefits using EHR data. Since RWD are becoming more and more 
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important in clinical evidence generation, this offers a new way of analyzing treatment effects from 
personalized medicine perspective. 
 In the application, longitudinal pain score data of patients undergoing spine fusion surgery, 
extracted from Cerner HealthFacts® HER database, were modeled simultaneously with post-surgical LOS 
using a 2-PM model for joint mixed effects. This is another novelty of the current study. Previously, the 2-
PM model was defined as a mixed effects model of a single outcome of repeated measures with random 
effects for both the intercept and time-dependent covariates.  By extending the 2-PM model to allow for 
joint modeling of the outcome of interest and the hospital LOS, the prediction of individual treatment 
benefits can now handle longitudinal data with non-ignorable missingness. The correlation between the 
longitudinal outcome and the LOS is taking into consideration, leading to more reliable and accurate 
estimation of the model parameters. More accurate parameter estimates in turn lead to better prediction of 
individual treatment benefits.  
 Although the “predict” command in JMRE1 provides the EB estimates of the random effects in the 
joint mixed effects model, previous publications by the author did not explicitly describe the method used 
in the prediction (Touloumi et al. 1999, Pantazis et al. 2010).  In this study, we provided detailed 
information on the calculation of the random effects using matrix algebra. The joint model defines that the 
level 1 residual in the LOS model is always 0; therefore, the values of LOS model level 1 residuals as well 
as the variance were set to 0.  
 We are interested in longitudinal outcomes that decrease over time and stabilize at a minimum 
value. A transformation of the outcome is necessary to make sure the estimated outcomes are within a 
meaningful range. For discrete outcomes, like the pain scores we used in the application, a discrete logit 
transformation can be used as described in the Methods section. This is another contribution of the current 
study. To our best knowledge, there has been no publications in the literature that proposed this type of 
transformation for discrete outcomes such as patient-reported scores.  
 A lognormal accelerated failure time model was used to model the post-surgical hospital LOS. This 
is a reasonable model in terms of the pattern of the hazard of discharge. We are investigating patients 
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undergoing a major surgery, who would be unlikely to go home immediately after surgery and more likely 
to go home in the several days after the surgery, but then less likely to go home if they remain in the hospital 
longer due to any complications associated with the surgery.  
 We used two methods to estimate the individualized pain management benefits in the application. 
The results from the EB method are quite similar to those from Monte-Carlo computations. This confirms 
that the prediction of individualized benefits using EB-predicted random effects is reliable. In JMRE1, the 
“predict” command gives the EB-predicted random effects.  The makes it convenient for researchers to 
implement the prediction of individualized benefits for their data using the Stata.  
 The prediction performance using the 2-PM model for joint mixed effects was evaluated using 
Pearson’s correlation and relative bias comparing predicted benefits with true benefits for simulated new 
patients. Results showed that, except when only baseline data are available, the prediction of benefits is 
reliable, with small median relative biases and good correlations when the model parameter estimates are 
reasonably close to the true parameter values. When the model parameter estimates move further away 
from the true parameter values, the range of the predicted correlation or relative biases get wider, especially 
when the prediction origin t is small. As the prediction origin t goes larger, the results become more stable 
and less sensitive to the changes in δ.  
 In summary, we proposed to use a 2-PM model with joint mixed effects that simultaneously models 
the longitudinal outcome and the hospital LOS for predicting individualized treatment benefits using 
unbalanced continuous or discrete outcomes in EHR data. Evaluation of the prediction using simulations 
demonstrated that the prediction is reliable in the application used in this study, given that the parameter 
estimates are not far from the true parameter values. This method can be used to analyze individualized 
benefits for many longitudinal clinical outcomes in the EHR data. The JMRE1 command is conveniently 
available in Stata, making it practical for the application of this method.   
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Chapter 3: Effects of depression and age on individual benefits of pain management post spinal 
fusion: an analysis of longitudinal hospital data 
In collaboration with Drs. Nikos Pantazis, Ph.D., Jose de Leon, M.D., and Francisco J. Diaz, Ph.D. 
(See collaborator affiliations in Acknowledgements) 
3.0. Abstract  
Objectives:  This study analyzed the impact of depression and age on individual benefits of postoperative 
pain management in lumbar spinal fusion patients using longitudinal observational data.  
Methods: Cerner HealthFacts electronic health records were used. Patients were selected using 
International Classification of Diseases (ICD)-9 codes and ICD-10 codes for spinal fusion and 
predetermined inclusion/exclusion criteria. A joint multivariate mixed model of pain scores and length of 
hospital stay was used to analyze individual benefits. 
Results: Depression was significantly associated with higher baseline pain scores (p=0.001) on average, 
whereas geriatric age was associated with lower baseline pain scores (p=0.047). Antidepressant use had no 
significant effects on postoperative pain scores in patients with depression. Although pain management 
benefits tended to increase with time, the amount and rate of change of the benefits depended on depression 
status and age. More patients with depression received small benefits than those without depression after 
controlling for age and time. For patients with depression, non-geriatric age was associated with slower 
individual benefits development, except for those achieving the highest benefits. In general, the detrimental 
depression effects on individual benefits outweigh age effects in the patients achieving the highest benefits. 
Patients with higher immediate benefits tended to have shorter lengths of stay.   
Conclusions: This study revealed that preoperative depression and geriatric age may be important factors 
affecting individual benefits of postoperative pain management in patients undergoing spinal fusion 
surgery. Depression had a negative impact on pain relief, while age had varied effects depending on 
depression status and other traits. 
Keywords: individual benefits, random effects, depression, pain management, spinal fusion.  
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3.1. INTRODUCTION 
Although lumbar spinal fusion is the top procedure for treating chronic low back pain and is the 
second most common low back operation overall, better understanding is needed of how patients’ 
characteristics influence postoperative outcomes (Gaudin et al., 2017). Depression is known to be 
associated with chronic pain such as back pain (Trivedi, 2004) and is a negative predictor of spinal fusion 
outcomes (Gaudin et al., 2017). Retrospective cohort studies have found that: 1) patients with pre-existing 
depression were absent from work for more days after spinal fusion surgery compared to those without 
depression (Anderson et al., 2015), and 2) preoperative depression influences patient satisfaction 
independent of the surgery’s effectiveness (Adogwa et al., 2013). 
Patient-reported maximum pain levels on a scale from 0 to 10 are often used as postoperative 
quality measures to monitor pain relief and track patients’ progress after spinal fusion. Studies of risk factors 
for severe postoperative pain have provided varying results. The risk factors could be procedure-specific; 
however, preoperative chronic pain and younger age were associated with higher postoperative pain level 
independent of the type and extent of the surgery in pooled data from 150 German hospitals (Gerbershagen 
et al., 2014). In a German registry of knee replacement, older age was associated with lower reported 
maximum pain levels. On the other hand, the elderly patients did not report less functional impairment 
caused by pain, suggesting that they tend to underreport their pain levels (Weinmann et al., 2017). 
 It is important to further understand the impact of patients’ characteristics such as preoperative 
depression and age on individual benefits of pain management after spinal fusion surgery. Generalized 
linear mixed-effects modeling is a statistical approach useful for predicting individuated treatment benefits 
(Diaz, 2016 and 2019), which take into consideration the heterogeneity of patients’ characteristics including 
unknown traits. While traditional statistical analyses focus on average treatment effects, mixed-effects 
modeling can analyze the variation of treatment effects in individual patients.   
Electronic health records (EHR) provide valuable resources for longitudinal studies and 
understanding risk factors associated with poor clinical outcomes. However, they may not provide complete 
follow-up, and the missing data are not at random since hospital discharge may depend in part on expected 
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but unrecorded clinical outcomes after discharge (Ibrahim and Molenberghs, 2009). This is called “non-
ignorable missingness” and requires novel statistical techniques.14 Ignoring the unbalanced nature of 
longitudinal EHR data may lead to serious bias (Albers et al., 2018). 
In this study, we use novel statistical methods to evaluate the effects of depression and geriatric 
age (age>65 years) on patient-reported pain levels (Diaz, 2016 and 2019; Pantazis and Touloumi, 2010). 
The main goal is to measure and compare individual benefits of postoperative pain management, using 
EHR data from patients undergoing spinal fusion surgeries  (Cerner HealthFacts®; Kansas City, MO).  
3.2. METHODS 
Data source and study subjects 
The EHR dataset (Cerner HealthFacts®, Kansas City, MO) is deidentified and has been used in 
previously published articles (Shaw et al., 2018; Urman et al., 2018). An Institutional Review Board (IRB) 
exemption for this study was granted by Western IRB (Olympia, WA).  We selected adult inpatients 
undergoing spinal fusion surgery in the United States between January 1, 2014, and December 31, 2015, 
using International Classification of Diseases ICD-9 codes 81.00 to 81.08 and corresponding ICD-10 codes.  
Additional inclusion criteria were 1) at least one pain score on the day of surgery (day 0) and at 
least one score after that day; 2) a maximum score on day 0 between 7 and 10 inclusive; 3) 1 to 5 days post-
surgical hospital stay; and 4) at least 6 months of history captured in the database prior to the surgery. For 
greater sample homogeneity, patients from the hospital with the largest number of patients meeting the 
above criteria were selected for this study. The reason for choosing a single hospital is that each hospital 
may have different pain management protocols. We identified 940 patients who satisfied the inclusion 
criteria, and 330 from the hospital with the largest number of patients were selected (Table 1).  
Pain assessments 
The numerical patient-reported pain scores ranged from 0 to 10, with 10 indicating the most severe 
pain (0: no pain, 1-3: mild pain, 4-6: moderate pain, 7-10 severe pain). The outcome of interest was the 
patient’s maximum daily score, obtained at day 0 and during 1 to 5 days of post-surgical hospital stay (Table 
60 
2). Since patients’ pain levels were not measured after discharge, this longitudinal observational study 
conveys the challenges of a highly unbalanced dataset caused by non-random missing data. Since pain 
scores are usually lower on or after the discharge day, the assumption that missing data would be random, 
which is required by standard longitudinal statistical models, is violated (Ibrahim and Molenberghs, 2009). 
Depression assessments 
Depression comorbidity was defined as having ICD-9 codes (3004, 30112, 3090, 3091, and 311) 
or ICD-10 codes (F320, F321, F322, F323, F328, F3281, F3289, F329, F330, F331, F332, F333, F338, 
F339, F341, F4321) during the hospital stay or within 6 months before admission, or having received 
antidepressants during the stay.                        
Hospital length of stay (LOS) 
The patients’ hospital LOS after surgery may be affected by their characteristics and responses to 
postoperative pain management. Pain levels are usually not measured after discharge and even when 
patients are in the hospital their pain measurements may be terminated for various reasons. Ignoring this 
incomplete follow-up in the data analysis could lead to serious bias (Ibrahim and Molenberghs, 2009). 
Hence, there is a need to apply special methods that account for the relationship between pain scores and 
LOS and model the premature termination of measurements in some patients. 
Statistical model 
This study utilized a joint multivariate random-effects (JMRE) model (Touloumi et al., 1999; 
Pantazis and Touloumi 2010), which is a generalized linear mixed-effects model that accounts for non-
ignorable missingness. The model combined a model of daily maximum pain scores with a model of LOS 
(Table 3, Footnotes a-e).  The daily maximum pain scores were transformed to improve the model’s 
goodness-of-fit.  
The variables included in the pain model were older age (1 if age >65 years, 0 otherwise), 
depression (1 if the patient had depression comorbidity, 0 otherwise), time as the number of days from 
surgery, and the interaction between depression and time. The transformed pain scores followed a linear 
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time trend. The intercept and the time slope were considered random, meaning they were different for each 
patient (Diaz, 2016 and 2019). 
Details on the LOS model are provided in Table 3, Footnote c.  It was assumed that the random 
residual of the LOS model was correlated with both the random intercept and random time slope of the pain 
model. Initial explorations showed that gender and race had no significant effects on either the pain scores 
or LOS and were therefore not included in the final model.  
Individual pain management benefits 
The severity of the patient’s disease is defined as the probability of being outside the pain treatment 
target, which in turn is defined as a daily maximum pain score ≤6 (Table 4, Footnote a) (Diaz, 2016 and 
2019). The patient’s individual treatment benefit is defined as the decrease in disease severity from baseline 
(x100).  
 To examine how much benefit patients received from postoperative pain management during the 
5 days after spinal fusion, we predicted the individual benefits for each of the 330 patients. Estimated 
random effects for each patient were used to predict treatment benefits, combining all available patient data 
with parameter estimates in Table 2. Details regarding calculation of the empirical Bayes (EB) predictors 
of the benefits are provided in Table 4, Footnote a (Diaz, 2016 and 2019). 
For each patient, individual benefits were predicted from day 0.2 to day 5 by 0.2-day increments. 
Although patients’ pain scores were observed for days 0 to 5, benefits can be predicted for any non-integer 
interval from 0 to 5 days using the formula in Table 4, Footnote a (Diaz, 2016 and 2019). Median, 25th and 
75th percentiles of individual benefits were calculated. For each of the 4 groups determined by age and 
depression status, these statistics were plotted (Figure 1) and presented in Table 4 for days 1 through 5. To 
compare the evolution of individual benefits over time across the 4 groups, we plotted histograms of the 
benefits (Figure 2).  
3.3. RESULTS  
Patient Characteristics  
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Patients’ characteristics, pain medications and antidepressant medications are described in Table 1. 
Almost half (46%) the patients had comorbid depression. Depression was more frequent in females (54%, 
94/173) than in males (36%, 56/157) and in non-geriatric patients (49%, 132/271) than in geriatric patients 
(31%,18/59). Baseline pain scores and hospital LOS are in Table 2. 
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Table 1.  Demographics and clinical characteristics of 330 patients who underwent a spinal fusion 
surgery.            
 
       Mean  SD     
Age (years)      53.9 12.4     
       %      
GERIATRIC AGE (>65 years)  
 Yes       18 (59/330) 
 No       82 (271/330) 
GENDER     
 Female      52 (173/330) 
 Male       48 (157/330) 
RACE     
 Caucasian      93 (308/330)      
 African American        2 (7/330) 
 Other          5 (15/330) 
PAIN MEDICATION   
 Opioids and acetaminophen    78 (257/330) 
 Opioids, NSAIDs and acetaminophen   18 (60/330)   
 Opioids only         4 (12/330)  
 Opioids and NSAIDs       <1 (1/330)  
DEPRESSION 
 Yes       46 (150/330) 
 No       54 (180/330)  
ANTIDEPRESSANT MEDICATION 
 Taking antidepressants      81 (121/150)      
 SSRI        34 (51/150)      
 SNRI        11 (17/150) 
 Othera              9 (13/150) 
 SSRI and other               7 (11/150) 
 SSRI and TCA             5 (8/150) 
 TCA              5 (7/150)  
 SNRI and TCA                4 (6/150)  
 SSRI and SNRI              1 (2/150)  
 SNRI and other                1 (2/150)  
 MAOI            <1 (1/150) 
 Other and TCA             <1 (1/150) 
 SSRI, SNRI and other         <1 (1/150)  
 SSRI, other and TCA           <1 (1/150)                                  
Abbreviations: SD = standard deviation, MAOI = monoamine oxidase inhibitor, NSAID = nonsteroidal 
anti-inflammatory drug, SNRI = serotonin norepinephrine reuptake inhibitor, SSRI = serotonin selective 
reuptake inhibitor, TCA = Tricyclic antidepressant. 
aThe EHR database did not itemize the medications in the “Other” category. 
  
 
Joint model and the impact of depression and age on pain scores and LOS 
We found positive correlations between 1) high baseline pain scores and longer postoperative LOS 
(r=0.50, p<0.001), 2) slower pain reduction and longer LOS (r=0.67, p<0.001), and 3) high baseline pain 
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scores and slower pain reduction post-surgery (r=0.85, p<0.001).  These significant correlations indicated 
that 1) patients who had higher baseline pain scores tended to stay longer after surgery; 2) patients whose 
pain decreased more slowly after surgery tended to stay longer; and 3) patients with higher pain scores at 
baseline tended to have slower pain reduction after surgery. 
The pain model demonstrated that, on average: 1) a preoperative record of depression was 
significantly associated with higher baseline pain scores (P = 0.001; Table 3); 2) geriatric age was 
significantly associated with lower baseline pain scores (P = 0.047); 3) a significant interaction existed 
between depression and time (parameter estimate=0.1327, p=0.045), meaning that patients with depression 
had significantly slower pain reduction after surgery.  
The LOS model demonstrated that, on average: 1) geriatric age was significantly associated with 
longer LOS (p = 0.001; Table 3); and 2) depression tended to be associated with a slightly longer LOS, 
although it did not reach significance (P = 0.096).  
 
Table 2.  Mean and SD of stratified maximum baseline pain scores and hospital LOS after surgery in 330 
patients who underwent a spinal fusion surgery      
 
    Baseline Pain scores  LOS      
    Mean SD   Mean SD  Min   Max   
All (N=330)   8.65  1.11   1.62  1.00      1.0    5.0 
GERIATRIC AGEa 
  Yes (N=59)       8.31  0.99   1.98  1.17      1.0    5.0 
   No (N=271)   8.72  1.12   1.54  0.94      1.0    5.0 
GENDER 
  Female (N=173)       8.66  1.11   1.64  1.03      1.0    5.0 
  Male (N=157)   8.62  1.11   1.59  0.97      1.0    5.0 
RACE 
  Caucasian (N=308)       8.62  1.11   1.61  1.00      1.0    5.0 
  African American (N=7) 8.71  1.25   1.71  1.50      1.0    5.0 
  Other (N=15)   9.20  1.21   1.67  0.62      1.0    5.0 
DEPRESSION 
  Yes (N=150)       8.81  1.13   1.67  1.03      1.0    5.0 
   No (N=180)   8.51  1.07   1.57  0.97      1.0    5.0           
Abbreviations: SD = standard deviation, LOS = Length of stay.  





Table 3. Joint random-effects model of transformed daily maximum pain scores and hospital length of stay 
from 330 patients after spinal fusion surgery       
Parameter name   Estimate      P           95% CI   
FIXED EFFECTS FOR TRANSFORMED PAIN SCORESa,b 
  Pain score intercept   1.470    <0.0001     1.364 to1.577 
  Geriatric agee    -0.185    0.047     -0.337 to -0.003 
  Depressionf    0.228    0.001      0.102 to 0.393 
  Time (days)g     -0.677    <0.0001    -0.768 to -0.587 
  Interaction between depression and time 0.133    0.045      0.003 to 0.263 
FIXED EFFECTS FOR LOS (days)c,d 
  LOS intercept     0.247    <0.0001      0.171 to 0.322 
  Geriatric agee                   0.220    0.001       0.093 to 0.346 
  Depressionf     0.089    0.096      -0.016 to 0.193 
                                                                                
Abbreviation: CI = 95% confidence interval, LOS = length of stay.  
aA random effects linear model of the transformed maximum pain scores was fitted, simultaneously with an 
accelerated failure-time lognormal model of hospital LOS postsurgery.14 This joint mixed model accounted for the 
correlation between LOS and the evolution of pain scores after surgery. The distribution of the original pain scores 
was highly skewed with higher frequencies for severe pain scores. Maximum pain scores were previously transformed 
as log ((Pain Score𝑖𝑗 + 1)/(11 − Pain Score𝑖𝑗)), where Pain Score𝑖𝑗  is the maximum daily pain score for patient 
𝑖 at day Time𝑖𝑗 . After this transformation, the model fitted well according to residual and random effects analyses. 
The pain model included a random intercept and a random slope for time and had the form 
Transformed Pain Scores𝑖𝑗 = 𝛽0 +  𝛽1  × Geriatric Age𝑖 +  𝛽2 × Depression𝑖 +  𝛽3 × Time𝑖𝑗 + 𝛽4 ×
Depression𝑖  × Time𝑖𝑗 + 𝛼0𝑖  + 𝛼1𝑖  ×  Time𝑖𝑗 +  𝑒𝑖𝑗 ,   where 𝑒𝑖𝑗 indicates the residuals for the pain score model for 
patient 𝑖 at occasion 𝑗 which has mean 0 and residual variance 𝜎𝑒
2. The parameters 𝛽𝑘, 𝑘 = 1, … ,4, are population-
average effects (the fixed effects), whereas 𝛼0𝑖 and 𝛼1𝑖 are parameters specific to patient 𝑖 denoting deviations from 
the corresponding population-averages (the random effects). The joint mixed model was fitted using the “jmre1” Stata 
command (StataCorp LLC, College Station, TX)14 
bThe variances of the random effects were 0.1384 for the pain score intercept, and 0.0916 for the time slope. The 
residual variance for the pain model was 0.3835. 
cThe model of LOS for patient 𝑖 had the form log(LOS𝑖) = 𝛽0
𝑑 +  𝛽1
𝑑  × Geriatric Age𝑖 + 𝛽2
𝑑 × Depression𝑖 + 𝑒𝑖
𝑑, 
where 𝑒𝑖
𝑑 is a random residual following a normal distribution with mean 0. 
dThe variance of the LOS intercept was 0.2281. 
eThe dichotomous covariate geriatric age was defined as 1 if the age of the subject was >65, and 0 otherwise.  
fThe dichotomous covariate depression was defined as 1 if the patient had a record of depression diagnosis or was 
under antidepressants, and 0 otherwise.  




Impact of depression and age on individual benefits of postoperative pain management  
Although treatment benefits tended to increase over time for all four groups of patients, the amount 
and rate of change of achieved benefits varied across groups (Table 4). For instance, at day 1, in non-
geriatric patients without depression the median decrease in disease severity was 18.6% probability units 
compared to 5.6% in non-geriatric patients with depression  
 
Table 4. Sample medians (and first and third quartiles) of individual benefits (x100) of postoperative pain 
management on days 1 through 5 for 330 patients after spinal fusiona    
 
Study group  Day 1  Day 2  Day 3  Day 4  Day 5   
Age > 65 and  25.5  64.2  87.6  89.4  90.4  
No depression  (4.4, 34.2)  (15.4, 76.3) (34.6, 89.4) (58.3, 93.3) (76.2, 93.8) 
(N=49) 
Age ≤ 65 and  18.6  59.3  87.7  93.0  94.4  
No depression  (9.3, 37.1)  (35.9, 81.1) (70.9, 91.8) (87.3, 95.5) (89.7, 97.0) 
(N=191) 
Age > 65 and  12.1  40.3  72.5  89.3  91.6  
depression  (3.5, 19.1)  (12.2, 56.4) (28.9, 83.5) (52.6, 92.8) (75.1, 96.1) 
(N=10) 
Age ≤ 65 and  5.6  23.8  53.6  81.3  93.6  
depression  (1.3, 17.3)  (5.7, 56.1) (16.2, 87.3) (34.4, 95.2) (57.2, 96.9) 
(N=80)              
aThe individual benefit is the increase in the probability of being in the treatment target from baseline.7,8 The treatment 
target was defined as a maximum daily pain score ≤6, which corresponds to a transformed pain score ≤0.3365.  







)} × 100,  with  ?̂?𝑖(𝑡) = ?̂?0 + ?̂?1  × Geriatric Age𝑖 + ?̂?2 × Depression𝑖 +  ?̂?3 ×
𝑡 +  ?̂?4 × Depression𝑖  × 𝑡 + ?̂?0𝑖  + ?̂?1𝑖  × 𝑡, where ?̂?𝑖(𝑡) is the patient’s predicted transformed pain score 
at time 𝑡; ?̂?𝑗 is the maximum likelihood estimator of 𝛽𝑗 for 𝑗 = 1, … ,4; ?̂?0𝑖 and ?̂?1𝑖 are the empirical Bayes predictors 
of 𝛼0𝑖 and 𝛼1𝑖, respectively; Φ is the standard normal cumulative distribution function; and ?̂?𝑒 is the estimated standard 
deviation of the pain model residuals 𝑒𝑖𝑗.The empirical Bayes predictors of the random effects of each patient were 
calculated using the “predict” command of the “jmre1” Stata command (StatCorp LLC, College Station, TX). 
 
By day 5, the median achieved benefits were comparable for patients with or without depression. 
However, the first quartiles for patients with depression tended to be smaller than those for non-depressive 
patients of comparable age group at specific times, indicating that there were more patients with depression 
receiving small benefits than patients without depression after controlling for age and time. 
67 
Figure 1. Predicted evolution of individual pain management benefits (x100) after a spinal fusion surgery 
over days 1 through 5 for 330 patients. For a particular patient, predicted individual treatment benefits were 
obtained by combining the patient’s data with the parameter estimates in Table 2. (A), (B), and (C) show 






For patients with depression, non-geriatric age was associated with slower individual benefits 
development. For instance, in geriatric patients with depression, the median decrease in disease severity 
was 12.1% probability units at day 1 compared to 5.6% for non-geriatric patients with depression. On day 
5, the first quartile for geriatric patients with depression (75.1%) was higher than that for non-geriatric 
patients with depression (57.2%). Figure 1A illustrates that for average patients with depression non-
geriatric age was associated with smaller benefits, compared to geriatric age. In general, average patients 
with depression had much smaller benefits after controlling for age.      
In patients receiving the poorest benefits from pain management the combination of depression and 
non-geriatric age was associated with the slowest responses whereas non-geriatric age without depression 
was associated with the fastest responses (Figure 1B).  Interestingly, for the patients achieving the greatest 
benefits (Figure 1C), individual benefits were more clearly affected by depression comorbidity than by age.  
Figure 2 suggests that preoperative depression diagnosis was associated with slower pain reduction 
after controlling for age and time. The number of non-geriatric patients who received substantial benefits 
on a given day post-surgery was higher for the group without than for the group with depression (Figure 2, 
69 
left panels). Even by day 5 post-surgery, there was still a much higher number of patients in the group with 
depression who only received minimal benefits from pain management.  Similar patterns were seen in 
geriatric patients (Figure 3, right panels).  
Effect of antidepressants on individual benefits of postoperative pain management in patients with 
depression 
To assess whether treatment with antidepressants influenced response to pain management in 
patients with depression, we fitted an additional joint mixed model using only patients with depression, 
similar to the model in Table 3 except that the depression variable was replaced by antidepressant use. 
Antidepressant use was not significantly associated with baseline pain scores (p=0.283) and did not 
significantly modify postoperative pain reduction (p=0.53). There were no significant differences in 
hospital LOS (p=0.792) after surgery between patients with and without antidepressant use. Furthermore, 
geriatric age was not significantly associated with baseline pain scores (p=0.099) or LOS (p=0.126). 
Individual benefits one day after surgery as predictors of LOS  
To examine whether levels of individual benefits from post-surgery pain management achieved 
after 1 day are predictive of hospital LOS, we compared the LOS from patients whose individual benefits 
were between the 1st, 2nd, 3rd, and 4th quartiles (Table 5). Patients with higher immediate benefits tended to 
have shorter LOS.  
 
Table 5. Hospital LOS (in days) for study patients grouped by quartiles of individual pain management 
benefits at day 1 post spinal fusion surgery         
Individual Benefits   N Mean (SD) Median Minimum Maximum  
1st quartile (0 to 3.28%) 82 2.44 (1.25) 2  1  5 
2nd quartile (3.29 to 13.64%) 83 1.69 (0.96) 1  1  5  
3rd quartile (13.65 to 27.92%) 84 1.19 (0.50) 1  1  3  
4th quartile (≥27.93%)  81 1.15 (0.45) 1  1  3   




Figure 2. Histograms of predicted individual pain management benefits (x100) after a spinal fusion surgery 
on days 1 through 5 in patients with age ≤ 65 with or without depression (left panels) and age > 65 with or 
without depression (right panels), assuming the model in Table 2. (A), (C), (E), (G), and (I) are benefits for 
patients with age ≤ 65 with or without depression on days 1, 2, 3, 4, and 5, respectively. (B), (D), (F), (H), 











3.4. DISCUSSION  
Strengths of our statistical model  
Unlike randomized clinical trials, EHR data are longitudinally unbalanced due to incomplete 
follow-up. This type of data is likely to have non-ignorable missingness (Touloumi, 1999; Pantazis and 
Touloumi, 2010) caused by termination of pain measurements due to discharge. The simultaneous modeling 
of LOS and pain took into consideration the correlations between them. It reduced the bias associated with 
unbalanced data and provided more accurate estimation of the effects of age and depression on pain scores.   
Another novelty of this study is the assessment of the impact of preoperative depression and age 
on the individual benefits of post-operative pain management instead of focusing only on average effects. 
These analyses are more consistent with the goals of personalized medicine (Diaz, 2016 and 2019). 
Limitations 
 Our study included patients with severe pain at baseline and at least one pain score and who stayed 
at least 1 day in the hospital. These criteria may have excluded less severe cases so our results cannot be 
extrapolated to them. Moreover, to increase homogeneity we selected our sample from the hospital with 
more cases in the EHR database. There is no way of knowing how representative this hospital sample was, 
although this is a typical limitation of observational data. 
The pain scores used in this study were self-reported values. Patient-reported measures such as pain 
scores and levels of satisfaction are important measures for evaluating treatment effects (Lotzke, 2016). 
They could be biased, however, since each patient may have different levels of sensitivity and expectation. 
However, predictors of individual benefits, which are on a probability scale, compare baseline pain 
severities with post-treatment severities within a patient, canceling out potential individual biases in the 
perception of pain. 
Comparison with prior studies 
 In the present study, almost half (46%) the patients undergoing spinal fusion surgery had 
depression. Pain scores decreased at a slower pace after surgery in patients with depression. The effect of 
geriatric age was not as dramatic but did have an impact on the individual benefits of pain management in 
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subsets of patients. For example, we could see the effects of geriatric age in those who were not doing so 
well and those with average benefits, although geriatric age did not show substantial effects on the benefits 
for the patients who were responding well. We also found associations between higher baseline pain scores, 
longer LOS, and slower speeds of postoperative pain relief. Our study confirms the finding from earlier 
studies that a high proportion of patients with chronic pain have depression (Greden, 2009). It has been 
demonstrated that depression and chronic pain go together, making it hard to determine cause and effect 
(Gaudin, 2017; Trivedi, 2004; Anderson et al., 2015; Greden, 2009; Arnold et al., 2012). Several studies 
showed that depression and age both have an impact on the feeling of pain (Gaudin, 2017; Trivedi, 2004; 
Anderson et al., 2015; Gerbershagen et al., 2014; Weinmann et al., 2017). Geriatric patients tend to report 
lower pain levels, which could be due to their decreased sensitivity to pain (Gerbershagen et al., 2014; 
Weinmann et al., 2017). 
An earlier study found that females tended to have slightly higher postoperative pain levels as 
compared to males (Gerbershagen et al., 2014). In our study, however, gender was not significant in a joint 
mixed model that adjusted for depression. More females (35%) had a preoperative depression diagnosis 
than males (19%), and the p-value for gender before adjusting for depression was smaller although still not 
significant (p= 0.178). Thus, it is possible that depression mediated the previously reported relationship 
between female gender and pain to some degree.  
Antidepressants had no significant effects 
To rule out the possibility that antidepressant medication explains the observed slower response to 
pain management in patients with depression, we analyzed the effects of antidepressant treatments in 
patients with depression. We found that antidepressants were not significantly associated with baseline pain 
scores or the response to pain management. Thus, the slow response to pain management in patients with 
depression may be due to the comorbidity itself instead of antidepressant medication.  
Individual benefits 
This study compared individual benefits of pain management among four groups of patients 
determined by depression diagnosis and age. An examination of median benefits was not enough, and other 
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subgroups of individuals emerged (Figure 1). In “average” patients, age played an important role in those 
with depression, who were prone to receive less benefit (Figure 1A).  In contrast, among patients tending 
to receive the smallest benefits (Figure 1B), younger patients without depression achieved some benefit 
quicker than geriatric patients with depression, whereas younger patients with depression were the least 
benefitted from pain management. Moreover, among patients achieving the highest benefits (Figure 1C), 
the effect of age on treatment benefits was negligible compared to the effect of depression. Our finding that 
the effect of age is unimportant in patients receiving high benefits is consistent with the results of a previous 
study that found that, although elderly patients reported lower pain scores post total knee replacement, their 
functional impairment caused by pain did not differ from younger patients.6 
LOS 
Interestingly, patients who received less benefit from one day of post-surgery pain management 
tended to stay longer at the hospital (Table 5), suggesting that early benefit measurements may serve as 
predictors of hospital LOS after surgery.  
Conclusion 
Our study revealed that preoperative depression and geriatric age are important factors affecting 
individual benefits of postoperative pain management in patients undergoing spinal fusion surgery. 
Depression had a negative impact on pain relief, while age had varied effects depending on depression 
status and potentially other traits. Moreover, joint mixed models are useful tools for analyzing unbalanced 
longitudinal EHR data caused by hospital lengths of stay that are related to treatment response. Finally, 
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3.6. Appendix: Stata Code 
3.6.1. Stata Code for Chapter One 
evaluate_disorganized.do.  
(Stata do file. Run simulations from this file.) 
trueparam_disorganized, delta(0.5) canna01(0) predorig(3) h(1) numpat(1000) reseed(24) 
display "canna01: "$canna01 
display "Prediction origin: t="$PredOrig 
display "Prediction horizon: h="$h 
display "delta= " $delta 
display "Median of relative biases: " r(MedianRelBias)   
display "Minimum of relative biases: " r(MinRelBias)      
display "Maximum of relative biases: " r(MaxRelBias)      
display "Median of correlations between predicted and true transformed benefits:  " r(MedianCorr)      
display  "Minimum of correlations: " r(MinCorr)  
display "Maximum of correlations:  " r(MaxCorr)     
trueparam_disorganized.ado.  
(Stata ado program that performs the Monte Carlo simulations. This program is called by 
evaluate_disorganized.do) 
program trueparam_disorganized, rclass 
version 15.1 
syntax, delta(numlist max=1 >=0)  canna01(numlist integer >=0 <=1) predorig(integer) h(integer) /// 
  [numpat(integer 1000) reseed(integer -1 )]  
clear  
*Seed for simulating random effects with drawnorm command 
if `reseed'<0 { 




global reseed "seed(`reseed')" 
} 
****************** 
global canna01=`canna01'  // enter 1 if patient used cannabis 
******************* 
global PredOrig=`predorig' //PredOrig is the prediction origin (a time point). 
global h=`h'  //h=horizon; enter a negative number or 0 for retrospective measurement of benefits; 
********************** 
global NumPat=`numpat'   //Enter number of simulated patients 
******************* 
global delta=`delta'   // Enter distance from a true parameter to parameter estimate in Table 1 in standard 
error units 
********************** 
* 64 is the total number of possible combinations of true parameter values for a fixed value of delta. 
* There are 6 model parameters and, therefore,  2^ 6 = 64 
set matsize 64   
if $NumPat>64 { 
if $NumPat<=11000 set matsize $NumPat 
else { 







clear     




quietly summarize MeanBias,detail  
return scalar MedianMeanBias=r(p50) 
return scalar MinMeanBias=r(min) 
return scalar MaxMeanBias=r(max) 
quietly summarize SDBias, detail 
return scalar MedianSDBias=r(p50) 
return scalar MinSDBias=r(min) 
return scalar MaxSDBias=r(max) 
quietly summarize RelBias, detail 
return scalar MedianRelBias=r(p50) 
return scalar MinRelBias=r(min) 
return scalar MaxRelBias=r(max) 
quietly summarize Correlation, detail 
return scalar MedianCorr=r(p50) 
return scalar MinCorr=r(min) 
return scalar MaxCorr=r(max) 
quietly summarize MeanTrueBenef, detail 
return scalar MedianMeanTrueBenef=r(p50) 
return scalar MinMeanTrueBenef=r(min) 





(Stata ado program used by trueparam_disorganized.) 
set more off 
set matsize 11000 
*This reads the estimates of the model reported in Table 1 of paper 
estimates use  "Fitted_model" 
*This gets the variance covariance matrix of estimates 
matrix VCe=e(V) 
******************************************** 






matrix bGLS=($b1   \   /// 
              $b2   \   /// 
  $b3   \   /// 
   $b4   \   /// 
   $b5) 
*The variance-covariance matrix D of random effects from model in Table 1 is created 
global D11=_b[/var(_cons[id])] 




(Stata ado program used by trueparam_disorganized.) 
if $delta!=0 {                       
    matrix Results=J(64,5,0)   //2^6=64 
    local deltalist -$delta  $delta 
    } 
else { 
    matrix Results=J(1,5,0) 
    local deltalist 0 
     }  
***********************  
matrix colnames Results = MeanBias SDBias RelBias Correlation MeanTrueBenef 
local RowOfResults=1   
foreach delta1 of numlist `deltalist' { 
foreach delta2 of numlist `deltalist' { 
foreach delta3 of numlist `deltalist' { 
foreach delta4 of numlist `deltalist' { 
foreach delta5 of numlist `deltalist' { 
foreach delta6 of numlist `deltalist' { 
*True fixed effects are computed 
global b1True=$b1 + `delta1'*sqrt(VCe[5,5])           
global b2True=$b2 + `delta2'*sqrt(VCe[1,1]) 
global b3True=$b3 + `delta3'*sqrt(VCe[2,2]) 
global b4True=$b4 + `delta4'*sqrt(VCe[3,3]) 
global b5True=$b5 + `delta5'*sqrt(VCe[4,4]) 
matrix bTrue=($b1True   \   /// 
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               $b2True   \   /// 
  $b3True   \   /// 
  $b4True   \   /// 
  $b5True) 
matrix list bTrue 
*True variance covariance matrix is computed 
global D11True=$D11+`delta6'*sqrt(VCe[6,6])   /* variance of intercept */          
matrix DTrue=$D11True 
***************************************** 
display "Simulation `RowOfResults' for canna01=$canna01, Delta=$delta, Prediction Origin=$PredOrig, 
Horizon=$h" 
clear 





matrix Results[`RowOfResults',5]=$MeanTrueBenef   










(Stata ado program used by trueparam_disorganized.) 
*Design matrix Z for random effects    
matrix A=J(7, 1, 1) 
matrix pt1=J(7, 1, 0) 
forvalues i=1/7{ 
 matrix pt1[`i', 1]=P[1,1]*(`i'-1) + P[1,2]*(`i'-1)^2 + P[1,3]*(`i'-1)^3 + P[1,4]  
}     
matrix Z=A  
matrix colnames Z=Intercept  
**********************************************    
*Design matrix X for fixed effects              
matrix A=J(7, 1, 1) 
matrix B=J(7, 1, $canna01) 
matrix pt2=J(7, 1, 0) 
forvalues i=1/7{ 
 matrix pt2[`i', 1]=P[2,1]*(`i'-1) + P[2,2]*(`i'-1)^2 + P[2,3]*(`i'-1)^3 + P[2,4]   
} 
matrix pt3=J(7, 1, 0) 
forvalues i=1/7{ 
 matrix pt3[`i', 1]=P[3,1]*(`i'-1) + P[3,2]*(`i'-1)^2 + P[3,3]*(`i'-1)^3 + P[3,4]   
}  
matrix X=A,B,pt1,pt2,pt3 





     
  if $PredOrig==0 { 
  matrix Z=Z[1..1,1...]   // 
  matrix X=X[1..1,1...] 
   } 
  if $PredOrig==1{ 
  matrix Z=Z[1..2,1...] 
  matrix X=X[1..2,1...] 
  } 
  if $PredOrig==2{ 
  matrix Z=Z[1..3,1...] 
  matrix X=X[1..3,1...] 
  } 
  if $PredOrig==3{ 
  matrix Z=Z[1..4,1...] 
  matrix X=X[1..4,1...] 
  } 
  if $PredOrig==4{ 
  matrix Z=Z[1..5,1...]               
  matrix X=X[1..5,1...]              
   }    
     if $PredOrig==5{ 
  matrix Z=Z[1..6,1...] 
  matrix X=X[1..6,1...] 
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  } 
   
       if $PredOrig==6{ 
  matrix Z=Z[1..7,1...] 
  matrix X=X[1..7,1...] 
  } 
} 
else{ 




if !(1<=$PredOrig+$h & $PredOrig+$h<=6) { 




*First we simulate the patients 
*The simulated random intercept LambdaR has mean zero  
clear   
quietly drawnorm  LambdaR, n($NumPat)  cov(DTrue)  $reseed  // DTrue was created in Module2 
mkmat LambdaR, matrix(RanEff)  // Each row of matrix RanEff corresponds to a set of random effects (for 
intercept and ptime1) for one simulated patient 
*Columns of matrix MatbTrue will contain the true fixed effects repeatedly  
matrix MatbTrue=bTrue 
forvalues i=2/$NumPat { 
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 matrix MatbTrue=MatbTrue,bTrue    // each column has a vector of bTrue 
} 
*Calculate linear predictor 
matrix RanEfft=RanEff' 
matrix ZR=Z*RanEfft  
matrix XB=X*MatbTrue 
matrix ata=ZR+XB 
*For each element of anta, calculate p. This will be the predicted P, which can be used to calculate the 
predicted benefit as well as to simulate y. 
matrix p=J(rowsof(ata), colsof(ata), 0)  // number of time points by number of patients  
matrix y=J(rowsof(ata), colsof(ata), 0) 
/* begin loop */ 
local i=1            // i for time 
while `i'<=rowsof(ata){ 
  local j=1          // j for patients 
  while `j'<=colsof(ata){ 
    matrix p[`i',`j']=exp(ata[`i',`j'])/(1+exp(ata[`i',`j']))  
     
 matrix y[`i',`j']=rbinomial(1, p[`i',`j'])    
    
    local j = `j' + 1 
  } 
   local i = `i' + 1 
}  
/* end loop */ 
*Create dataset xy with y and Xs for 1000 patients in rows by appending matrices. Include patient id 
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matrix X1=X 
forvalues i=2/$NumPat { 
 matrix X1=X1\X 
} 
matrix y1=y[1..., 1] 
forvalues j=2/$NumPat { 
 matrix y2=y[1..., `j'] 
 matrix y1=y1\y2 
} 
matrix id=J(rowsof(ata), 1, 1) 
forvalues j=2/$NumPat { 
 matrix id2=J(rowsof(ata), 1, `j') 
 matrix id=id\id2 
} 
matrix xy=y1, X1, id     
matrix colnames xy=dis_lt4 Intercept canna01 pt1 pt2 pt3 id   
// convert to dataset 
clear 
svmat xy, names(col) 
predict PrRanEff* , reffects 
duplicates drop id, force 
keep PrRanEff* id 
svmat RanEff, names(col)  
spearman PrRanEff1 LambdaR  
******************************************************************************** 
*Compute predicted benefit and true benefit for each patient 
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quietly generate ppred2=1/(1+ exp(-($b1 + PrRanEff1 + $b2*$canna01  + $b3 * pt1[$PredOrig+$h+1, 1] 
+ ///              $b4 * pt2[$PredOrig+$h+1, 1] + $b5 * pt3[$PredOrig+$h+1, 1] ))) 
quietly generate ppred1=1/(1+ exp(-($b1 + PrRanEff1 + $b2*$canna01 + $b3* pt1[1, 1] + /// 
       $b4 * pt2[1, 1] +  $b5 * pt3[1, 1] ))) 
quietly generate PredBenef=ppred2-ppred1 
quietly generate ptrue2=1/(1+ exp(-($b1True + LambdaR + $b2True*$canna01  + $b3True * 
pt1[$PredOrig+$h+1, 1] + /// 
       $b4True * pt2[$PredOrig+$h+1, 1] + $b5True * 
pt3[$PredOrig+$h+1, 1] ))) 
quietly generate ptrue1=1/(1+ exp(-($b1True + LambdaR + $b2True*$canna01  + $b3True * pt1[1, 1] + /// 
       $b4True * pt2[1, 1] + $b5True * pt3[1, 1] ))) 
quietly generate TrueBenef=ptrue2-ptrue1 
keep PredBenef TrueBenef 
******************************************************************************** 
*Individual bias is computed 
quietly generate double Bias=PredBenef-TrueBenef 
*Individual relative bias is computed 
quietly summarize Bias, detail 
global MeanBias=r(mean)  //Mean bias 
global SDBias=sqrt(r(Var))  // SD of bias 
quietly summarize TrueBenef, detail 
global MeanTrueBenef=r(mean) 
global RelBias=($MeanBias/$MeanTrueBenef)*100  // Relative bias 
******************************************************************************** 
*Computation of correlation between predicted and true benefit 
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quietly spearman TrueBenef PredBenef 
global Correlation=r(rho)    
end 
3.6.2. Stata Code for Chapter Two 
evaluate.do.  
(Stata do file. Run simulations from this file.) 
trueparam, delta(0) age(0) depress(0) predorig(5) h(0) numpat(1000) reseed(24) erseed(30) 
display "age: "$age 
display "depress: "$depress 
display "Prediction origin: t="$PredOrig 
display "Prediction horizon: h="$h 
display "delta= " $delta 
display "Median of relative biases: " r(MedianRelBias)   
display "Minimum of relative biases: " r(MinRelBias)      
display "Maximum of relative biases: " r(MaxRelBias)    
display "Median of correlations between predicted and true transformed benefits:  " r(MedianCorr)      
display  "Minimum of correlations: " r(MinCorr)  
display "Maximum of correlations:  " r(MaxCorr)     
trueparam.ado. 
(Stata ado program that performs the Monte Carlo simulations. This program is called by evaluate.do.) 
program trueparam, rclass 
version 15.1 
syntax, delta(numlist max=1 >=0) age(numlist integer >=0 <=1) depress(numlist integer >=0 <=1) 
predorig(integer) h(integer) /// 




display as error "reseed has to be different from erseed." 
exit, clear 
} 
*Seed for simulating random effects with drawnorm command 
if `reseed'<0 { 
global reseed " " 
} 
else { 
global reseed "seed(`reseed')" 
} 
*Seed for simulating model error terms 
if `erseed'<0 { 
global erseed " " 
} 
else { 
global erseed "seed(`erseed')" 
} 
****************** 
global age=`age'     // enter 1 if patient's age >65, 0 otherwise 
global depress=`depress'   // enter 1 if patient had depression, 0 otherwisec 
global delta=`delta' 
******************** 
global y=0.3365     // The treatment target is <=6; The transformation log((6+1)/(11-
6)) gives 0.3365 
global PredOrig=`predorig'  //PredOrig is the prediction origin (a time point).     
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global h=`h'     //h=horizon 
********************** 
global NumPat=`numpat'    //Enter number of simulated patients 
* 4096 is the total number of possible combinations of true parameter values for a fixed value of delta. 
* There are 12 model parameters that we need to calculate the true benefit and, therefore, 2^12=4096) 
set matsize 4096     
if $NumPat>4096 { 
if $NumPat<=11000 set matsize $NumPat 
else { 











quietly summarize RelBias, detail 
return scalar MedianRelBias=r(p50) 
return scalar MinRelBias=r(min) 
return scalar MaxRelBias=r(max) 
quietly summarize Correlation, detail 
return scalar MedianCorr=r(p50) 
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return scalar MinCorr=r(min) 




(Stata ado program used by trueparam.) 
set matsize 11000 
**** This reads the estimates of the model reported in Table 1 of paper  
estimates use "Fitted_model.ster" 
**** Covariance matrix  
matrix D=e(cov_re) 
global D11 D[1, 1]   
global D12 D[1, 2] 
global D13 D[1, 3] 
global D21 D[2, 1] 
global D22 D[2, 2] 
global D23 D[2, 3] 
global D31 D[3, 1] 
global D32 D[3, 2] 
global D33 D[3, 3] 
**** Extract fixed effects 
matrix B=e(b)' 







matrix b=( $b4 \   /// 
              $b5 \   /// 
  $b6 \   /// 
  $b7 \   /// 
  $b8)    
**** This gets the variance covariance matrix of fixed effects estimates 
matrix VCe=e(V)   // We will need the SE for fixed effects of the marker model in module 2. 
**** Variance of the error term for the pain score model in Table 1 
global VarErr=e(var_eij) 
**** Obtaining standard error of determinant of principal minor of D (eliminating 3rd row and 3rdcolumn) 
local D11 D[1, 1]   
local D12 D[1, 2] 
local D13 D[1, 3] 
local D21 `D12' 
local D22 D[2, 2] 
local D23 D[2, 3] 
local D31 `D13' 
local D32 `D23' 
local D33 D[3, 3] 
**** Computation of principal minor of D and its SE 
global pminor2=`D11'*`D22'-(`D21')^(2) 
global SEpminor2=$pminor2*0.6  // We have to give a value since we cannot calculate the SE of principal 
minor  








(Stata ado program used by trueparam.) 
 if $delta!=0 { 
 matrix Results=J(4096,2,0)  
    local deltalist -$delta  $delta 
    } 
else { 
 matrix Results=J(1,2,0) 
    local deltalist 0 
     }  
***********************  
matrix colnames Results = RelBias Correlation 
local RowOfResults=1   
foreach delta1 of numlist `deltalist' { 
foreach delta2 of numlist `deltalist' { 
foreach delta3 of numlist `deltalist' { 
foreach delta4 of numlist `deltalist' { 
foreach delta5 of numlist `deltalist' { 
foreach delta6 of numlist `deltalist' {    
foreach delta7 of numlist `deltalist' {   
foreach delta8 of numlist `deltalist' {    
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foreach delta9 of numlist `deltalist' {   
foreach delta10 of numlist `deltalist' {   
foreach delta11 of numlist `deltalist' {   
foreach delta12 of numlist `deltalist' {   
**** True fixed effects are computed 
global b4True=$b4 + `delta1'*sqrt(VCe[4,4]) 
global b5True=$b5 + `delta2'*sqrt(VCe[5,5]) 
global b6True=$b6 + `delta3'*sqrt(VCe[6,6]) 
global b7True=$b7 + `delta4'*sqrt(VCe[7,7]) 
global b8True=$b8 + `delta5'*sqrt(VCe[8,8]) 
matrix bTrue=($b4True   \   /// 
               $b5True   \   /// 
  $b6True   \   /// 
  $b7True   \   /// 
   $b8True ) 





local pminor2True=$pminor2+`delta9'*$SEpminor2  //The Variance-Covariance matrix was 
reparametrized to get a positive definite matrix 





local detDTrue=$detD+`delta11'*$SEdetD   //The Variance-Covariance matrix of random effects was 
reparametrized to get a positive definite matrix 
global D33True=((`detDTrue'+$D11True*($D32True)^(2)-(2*$D21True*$D32True-
$D22True*$D31True)*$D31True  ) / ($D11True*$D22True-($D21True)^(2))) 
matrix DTrue=( $D11True  , $D12True  , $D13True  \   /// 
             $D21True  , $D22True  , $D23True  \  /// 
   $D31True  , $D32True  , $D33True  ) 
***************************************** 
**** True error variance is computed 
global VarErrTrue=$VarErr+`delta12'* 0.38353*0.2 
*TrueParam_Module3 simulates the random effects, creates design matrices of the appropriate size 
(according to PredOrig and h), 
*and simulates the responses of patients, which are placed in matrix Y.  
*The random effects plus their corresponding fixed effects are also saved in the database temporarily. 




*TrueParam_Module4 computes the BLUPs. They are saved in database. 
TrueParam_Module4  
*TrueParam_Module5 computes the empirical Bayesian predictors of benefits and true benefits (and save 




















(Stata ado program used by trueparam.)     
if $PredOrig==0|$PredOrig==1|$PredOrig==2|$PredOrig==3|$PredOrig==4 |$PredOrig==5 {     
  if $PredOrig==0 { 
  matrix Z=(0, 1, 0 \ /// 
        1, 0, 0)    
  matrix X=(0, 0, 0, 1, 1*$age, 1*$depress, 0, 0*$depress \  /// 
   1, 1*$age, 1*$depress, 0, 0, 0, 0, 0) 
  local errors "eps01"    
  } 
  if $PredOrig==1{ 
  matrix Z=(0, 1, 0 \ /// 
        0, 1, 1 \ /// 
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        1, 0, 0)    
  matrix X=(0, 0, 0, 1, 1*$age, 1*$depress, 0, 0*$depress \  /// 
              0, 0, 0, 1, 1*$age, 1*$depress, 1, 1*$depress \  /// 
  1, 1*$age, 1*$depress, 0, 0, 0, 0, 0) 
  local errors  "eps01 eps02" 
  } 
  if $PredOrig==2{ 
  matrix Z=(0, 1, 0 \ /// 
       0, 1, 1 \ /// 
       0, 1, 2 \ /// 
       1, 0, 0)    
  matrix X=(0, 0, 0, 1, 1*$age, 1*$depress, 0, 0*$depress \  /// 
                    0, 0, 0, 1, 1*$age, 1*$depress, 1, 1*$depress \  /// 
           0, 0, 0, 1, 1*$age, 1*$depress, 2, 2*$depress \  /// 
        1, 1*$age, 1*$depress, 0, 0, 0, 0, 0) 
  local errors "eps01 eps02 eps03" 
  } 
  if $PredOrig==3{ 
  matrix Z=(0, 1, 0 \ /// 
        0, 1, 1 \ /// 
        0, 1, 2 \ /// 
        0, 1, 3 \ /// 
        1, 0, 0)    
  matrix X=(0, 0, 0, 1, 1*$age, 1*$depress, 0, 0*$depress \  /// 
                    0, 0, 0, 1, 1*$age, 1*$depress, 1, 1*$depress \  /// 
        0, 0, 0, 1, 1*$age, 1*$depress, 2, 2*$depress \  /// 
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        0, 0, 0, 1, 1*$age, 1*$depress, 3, 3*$depress \  /// 
        1, 1*$age, 1*$depress, 0, 0, 0, 0, 0) 
  local errors  "eps01 eps02 eps03 eps04" 
  } 
  if $PredOrig==4{ 
  matrix Z=(0, 1, 0 \ /// 
       0, 1, 1 \ /// 
       0, 1, 2 \ /// 
       0, 1, 3 \ /// 
       0, 1, 4 \ /// 
       1, 0, 0)    
  matrix X=(0, 0, 0, 1, 1*$age, 1*$depress, 0, 0*$depress \  /// 
              0, 0, 0, 1, 1*$age, 1*$depress, 1, 1*$depress \  /// 
   0, 0, 0, 1, 1*$age, 1*$depress, 2, 2*$depress \  /// 
   0, 0, 0, 1, 1*$age, 1*$depress, 3, 3*$depress \  /// 
     0, 0, 0, 1, 1*$age, 1*$depress, 4, 4*$depress \  /// 
  1, 1*$age, 1*$depress, 0, 0, 0, 0, 0)               
  local errors "eps01 eps02 eps03 eps04 eps05" 
  }   
  if $PredOrig==5{ 
  matrix Z=(0, 1, 0 \ /// 
 0, 1, 1 \ /// 
 0, 1, 2 \ /// 
 0, 1, 3 \ /// 
 0, 1, 4 \ /// 
 0, 1, 5 \ /// 
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 1, 0, 0)    
  matrix X=(0, 0, 0, 1, 1*$age, 1*$depress, 0, 0*$depress \  /// 
            0, 0, 0, 1, 1*$age, 1*$depress, 1, 1*$depress \  /// 
 0, 0, 0, 1, 1*$age, 1*$depress, 2, 2*$depress \  /// 
 0, 0, 0, 1, 1*$age, 1*$depress, 3, 3*$depress \  /// 
   0, 0, 0, 1, 1*$age, 1*$depress, 4, 4*$depress \  /// 
  0, 0, 0, 1, 1*$age, 1*$depress, 5, 5*$depress \  /// 
 1, 1*$age, 1*$depress, 0, 0, 0, 0, 0)           
  local errors "eps01 eps02 eps03 eps04 eps05 eps06" 
  } 
} 
else{ 
display as error "Values for predOrig should be 0,1,2,3,4, or 5" 
exit, clear 
} 
matrix colnames Z=_D _M _Mtime 
matrix colnames X=_D _Dage _Ddepress _M _Mage _Mdepress _Mtime _Mdepresstime 
********************************************* 
if !(1<=$PredOrig+$h & $PredOrig+$h<=5) { 




*Variance covariance matrix of error terms 
matrix RTrue=I(rowsof(Z)-1)  *  $VarErrTrue 
*Simulation of pain scores Y  
101 
*First we simulate the patients 
 
*The random effects are simulated.  
*A particular value of vector (re_D re_M re_Mtime) correspond to one patient. 
*The simulated random variables  re_D re_M re_Mtime have mean zero  
clear   
quietly drawnorm  re_D re_M re_Mtime , n($NumPat)  cov(DTrue)  $reseed 
mkmat re_M re_Mtime, matrix(RanEff)  // Each row of matrix RanEff corresponds to one simulated patient 
*Random coefficients are computed 
*A random coefficient is what is usually called a random effect plus its corresponding fixed effect. 
quietly generate re_M_c=$b4True+re_M 
quietly generate re_Time_c=$b7True+re_Mtime   
*The errors are simulated 
quietly drawnorm  `errors', n($NumPat)  cov(RTrue)  $erseed // errors are generated 
mkmat `errors', matrix(Errors)    // Each row of matrix Errors contains errors for corresponding patient in 
RanEff  
*Columns of matrix MatbTrue will contain the true fixed effects repeatedly  
matrix MatbTrue=bTrue 
forvalues i=2/$NumPat { 
matrix MatbTrue=MatbTrue,bTrue 
} 
*Matrix of responses is computed 
*Each column of Y contains the simulated responses of the patient in corresponding column of RanEff' 
matrix Z2=Z[1..rowsof(Z)-1, 2..3] 
matrix X2=X[1..rowsof(X)-1, 4..8] 
matrix Y=Z2*RanEff'+X2*MatbTrue+Errors'    
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matrix colnames Y=Patient 
matrix rownames Y=PainScore 
end 
2.7.6. TrueParam_Module4.ado.  
(Stata ado program used by trueparam.) 
*Variance covariance matrix of error terms 
matrix R=I(rowsof(Z))  *  $VarErr 
matrix R[rowsof(Z),rowsof(Z)]=0 
*Columns of matrix MatbGLS will contain the estimated fixed effects B repeatedly  
matrix MatbGLS=B 











matrix Res2=Res[1..rowsof(Res)-1, 1...] 
matrix Res3=Res2\zero_pt 
*The EB predictors are computed 
matrix BLUP=D*Z'*inv(R+Z*D*Z')*Res3 
matrix rownames BLUP=re1 re2 re3  
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*EB predictors are saved in database 
matrix BLUPT=BLUP' 
svmat BLUPT, names(col) 
end 
TrueParam_Module5.ado.  
(Stata ado program used by trueparam.) 
*True benefit is computed  
*(True variance of error is in global macro VarErrTrue) 
quietly generate double TrueBenef=100*(normal(  ($y-(re_M_c + $b5True*$age + $b6True*$depress + 
re_Time_c *($PredOrig+$h) + $b8True*$depress*($PredOrig+$h) )   ) /sqrt($VarErrTrue) ) /// 
          -  normal(    ($y-(re_M_c 
+ $b5True*$age + $b6True*$depress) )   /sqrt($VarErrTrue)    )) 
label var TrueBenef "True benefit (x100)" 
*Predicted benefit is computed 
*(Computed with parameters in Table 1 of article) 
*(Variance of error from model in Table 1 is in global macro $VarErr) 
*The EB predictors of the pain score model random effects are in re2 re3. 
quietly generate double PredBenef=100*(normal(  ($y-($b4+re2 + $b5*$age + $b6*$depress + ($b7+re3) 
*($PredOrig+$h) + $b8*$depress*($PredOrig+$h) )   ) /sqrt($VarErr) ) /// 
          -  normal(    ($y-
($b4+re2 + $b5*$age + $b6*$depress) )   /sqrt($VarErr)    )) 
label var PredBenef "Predicted benefit (x100)" 
*Individual bias is computed 
quietly generate double Bias=PredBenef-TrueBenef 
*Individual relative bias is computed 
quietly summarize Bias, detail 
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global MeanBias=r(mean)  //Mean bias 
quietly summarize TrueBenef, detail 
global MeanTrueBenef=r(mean) 
global RelBias=($MeanBias/$MeanTrueBenef)*100  // Relative bias 
quietly correlate TrueBenef PredBenef 
global Correlation=r(rho) 
end 
 
